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EXECUTIVE SUMMARY 
 
Background 
 
Tobacco control efforts in Australia are considered a public health success story with 
smoking prevalence in Victoria dropping from 31% in 1987 to 13.3% in 2012. This 
success would not have come without the passionate and committed individuals and 
organisations who have worked tirelessly to reduce the harms from tobacco. 
 
Tobacco control has been so successful that the concept of the ‘tobacco endgame’ 
has been discussed seriously, with contemplation that there may be a time when 
tobacco is no longer a public health issue. 
 
VicHealth has been committed to reducing the harms from tobacco in Victoria since 
its inception in 1987. VicHealth’s investment in tobacco control in Victoria has been 
significant ranging from buying out tobacco sponsorship in sport to being a major 
funder of the Quit Program by Quit Victoria. Funding to the Quit Program has 
facilitated the delivery of mass media campaigns, smoking cessation support and 
world leading research. 
 
VicHealth’s continuing commitment to reducing the harms from tobacco is detailed 
in the VicHealth Action Agenda for Health Promotion (Action Agenda).  
 
To achieve the goals outlined in the Action Agenda, VicHealth will continue to invest 
in tobacco control initiatives known to reduce smoking prevalence such as mass 
media campaigns and smoking cessation support services, and also examine other 
approaches that can further reduce harms experienced by groups where smoking 
remains common.  
 
Smoking is well known to be a chronic relapsing condition and smoking cessation is 
extremely difficult. Given the difficulty of cessation, the concept of harm reduction 
has been explored for smokers who were unwilling or unable to quit as early as the 
1960s. However the history of tobacco harm reduction has been plagued by tobacco 
industry deception and interference. 
 
Tobacco harm reduction is a broad concept relating to reducing harm, not 
eliminating harm. Tobacco harm reduction encompasses a number approaches 
including: 
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a) protection from environmental tobacco smoke 
b) substitution of combustible tobacco products with non-combustible 
tobacco products such as smokeless tobacco, for example snus, and 
electronic nicotine delivery systems (ENDS) such as e-cigarettes 
c) regulating the design and ingredients of cigarettes including: 
i. establishment of upper limits for carcinogens and toxins in tobacco 
cigarettes 
ii. regulating the constituents of cigarettes to reduce their addictiveness 
and palatability 
iii. regulating the level of nicotine with an aim of achieving a zero nicotine 
level in all cigarettes 
iv. regulating cigarette filters. 
 
 
Exploring tobacco harm reduction approaches is consistent with the National Drug 
Strategy 2010-2015 - A framework for action on alcohol, tobacco and other drugs 
(the Strategy). The Strategy provides a framework for action which applies the three 
pillars of demand reduction, supply reduction and harm reduction to minimise harm. 
 
Discussions about tobacco harm reduction have gained momentum in recent years 
on the grounds that the significant reduction in smoking prevalence has not been 
shared equally across society, and the burden of morbidity and mortality caused by 
smoking falls disproportionately on the most disadvantaged groups in society. 
 
This was highlighted in the Smoking and Disadvantage Evidence Brief prepared by 
the Cancer Council Victoria for the Australian National Preventive Health Agency in 
2013, which outlined that there are a number of population groups in Australia 
experiencing smoking rates up to five times higher than the population average.  
 
Although population level approaches which change social norms have been a 
cornerstone of tobacco control in Australia, it has been noted that these strategies 
have fostered a social transformation that appears to involve active stigmatisation of 
smokers. There is concern that many of those experiencing stigmatisation as a result 
of tobacco control policies are already some of the most stigmatised and 
marginalised groups in society.  
 
There is also concern that the significant recent increases in tobacco prices through 
taxation results in disadvantaged groups spending a greater proportion of their 
income on tobacco compared to the most advantaged groups in society. This is likely 
to result in the exacerbation of poverty by increasing the incidence of financial stress 
associated with tobacco addiction. 
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Action is urgently needed to reduce tobacco related health inequity, and further 
discussion and research are required to establish the potential benefits for harm 
reduction approaches to help reduce tobacco related inequities. 
 
The potential of tobacco harm reduction approaches has also been driven by the 
natural experiment in harm reduction that has taken place in Sweden. The 
availability of smokeless tobacco in Sweden provides important evidence of proof of 
concept for a harm reduction strategy based on the principle of making alternative, 
lower hazard sources of nicotine easily available to smokers. The increased use of 
smokeless tobacco in Sweden over the past 20 years has coincided with substantial 
reductions in smoking prevalence and tobacco-related mortality. 
 
The introduction of ENDS has also reinvigorated discussion about tobacco harm 
reduction. However, the potential of ENDS to reduce harm from tobacco does not 
evoke the usual level of cohesiveness and consistency of messaging among the 
tobacco control community as other tobacco control initiatives do. The issue of ENDS 
and tobacco harm reduction has divided public health scientists and practitioners 
and resulted in duelling open letters to the Director-General of the World Health 
Organization (WHO).  
 
The proliferation of the sale and use of ENDS internationally (in particular e-
cigarettes, whose sales are predicted to surpass those of conventional cigarettes by 
2017), discussion about the tobacco endgame, and VicHealth’s Action Agenda have 
together provided the impetus to explore the concept of tobacco harm reduction 
within the Australian tobacco control context again. 
 
Summary of tobacco harm reduction forum discussions 
 
To commence exploring the position of tobacco harm reduction, VicHealth hosted an 
international tobacco harm reduction forum in Melbourne in July 2014. The two-day 
forum brought together national and international tobacco control experts to share 
their knowledge and experience about tobacco control, tobacco harm reduction and 
ENDS. Presentations were delivered on the following topics: 
• the necessity of tobacco harm reduction to eliminate tobacco-related harm 
• ethical considerations for tobacco harm reduction 
• possible scenarios if ENDS were to become available in Australia 
• past experiences of tobacco harm reduction and the precautionary principle 
• existing evidence in relation to ENDS 
• considerations for an economic evaluation of ENDS 
• international experience in relation to ENDS (United Kingdom, United States, 
and New Zealand) 
• challenges for future research. 
 
The forum format provided opportunity for open discussion and included a number 
of panel discussions. 
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The forum highlighted that there is a considerable level of consensus among the 
Australian tobacco control community about the potential of tobacco harm 
reduction within the Australian context, as well as a number of areas that require 
further discussion. A summary of these is provided below. 
 
Areas of consensus  
 
Harm reduction should not distract from existing tobacco control measures 
Although there may be a place for a tobacco harm reduction approach in Australia, it 
should not be at the expense of existing tobacco control strategies that are known to 
be effective in reducing population prevalence, including taxation, mass media 
communication, cessation services, smoke-free environments and advertising bans. 
 
The health risks of ENDS are less than that of tobacco products 
ENDS pose less risk to smokers and non-smokers than conventional tobacco 
cigarettes, particularly in the short term. However, the harms from long-term use 
are unknown, and close monitoring and research are required to identify any that 
may exist. It was agreed that it is likely to take many years and perhaps decades, to 
understand any long-term harms from ENDS use. 
 
Children must be protected 
There is a critical need to ensure that children are protected from ENDS. At a 
minimum, ENDS should not be available, promoted to, or designed to be attractive 
to people under the age of 18. 
 
Caution is needed in relation to tobacco industry involvement  
Tobacco industry involvement in the ENDS market is a serious concern. Article 5.3 of 
the WHO Framework Convention for Tobacco Control should be respected and the 
tobacco industry must not be allowed to use ENDS and harm reduction principles as 
an opportunity to engage with or influence policy makers or the policy-making 
process. 
 
Promotion and advertising of ENDS should be restricted  
ENDS should not be promoted as an effective smoking cessation aid until there is 
sufficient evidence to justify such a claim. 
  
The promotion and marketing of ENDS should be restricted. There was some 
difference of opinion about the level of restriction, but generally it was agreed that 
advertising restrictions should be similar to existing tobacco advertising restrictions. 
 
Consumer safety is an important concern 
It was noted that there is a wide variability in the quality of ENDS products, with 
different models delivering highly variable amounts of nicotine, and cartridges 
containing nicotine solutions at concentrations different from those stated on the 
label, as well as containing other contaminants.  
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It was agreed that it was ideal to have a minimum product standard for ENDS, and 
that there is a need to have a single point of reputable evidence-based information 
for consumers and clinicians highlighting the safety concerns and factors consumers 
should consider when acquiring ENDS devices and nicotine-containing products.  
 
The regulatory framework governing ENDS is important 
The existing regulatory system is complex and imposes significant barriers to 
conducting research on ENDS in Australia.  
 
A robust regulatory system is required to protect young people, ban advertising and 
provide protection from environmental exposure, particularly for children.  
 
The regulatory system needs to be adaptable to respond to changes in products and 
to new evidence. The existing complex multijurisdictional regulatory system may not 
provide the appropriate level of adaptability to respond. 
 
Potential risks are associated with the introduction of ENDS 
It was agreed that the introduction of ENDS posed a number of risks; however, there 
was some disagreement about the extent to which those risks could outweigh the 
potential benefit. The potential risks associated with widespread use of ENDS in 
Australia include: 
• re-normalisation of smoking 
• potentially creating a new gateway for nicotine addiction and thereby 
smoking initiation by young people 
• dual-use of ENDS and tobacco cigarettes resulting in delayed smoking 
cessation. 
 
Research is required 
It was acknowledged that there is a significant level of research currently being 
undertaken internationally which will help inform the future policy direction in 
Australia in relation to ENDS and tobacco harm reduction.  
 
There was also overwhelming consensus that more research is required specific to 
the Australian context. At a minimum this should include the monitoring current and 
future ENDS use and supply in Australia through the adaptation and development of 
appropriate surveillance systems. 
 
As noted earlier, it was agreed that the existing regulatory system currently 
represents a considerable barrier to ENDS research, and that system modification is 
required to better facilitate this. 
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Areas requiring further discussion  
 
The best regulatory mechanism to enable ENDS availability in Australia 
There was a lack of consensus about the appropriate regulatory mechanism to 
enable ENDS availability in Australia. 
 
Approval through the Therapeutic Goods Administration (TGA), regulating ENDS as a 
tobacco product, and licencing users and retailers were all discussed as options. 
 
Controlled introduction of ENDS to monitor impact on population health 
There was a lack of consensus about whether the risks of a controlled introduction of 
ENDS in Australia to undertake in situ observational research outweighed the lost 
opportunity to reduce the harms from tobacco by restricting access while waiting for 
empirical evidence from other jurisdictions where ENDS are already widely available. 
 
Groups who would benefit most from ENDS 
It was agreed that further exploration was required to understand the profile of 
smokers who would benefit most from the introduction of ENDS in the Australian 
market. 
 
Opportunities to explore regulating the constituents of cigarettes 
It was agreed that there is need to better understand options, opportunities and 
mechanisms for regulating the constituents of cigarettes in the Australian context, 
including: 
• establishing upper limits for carcinogens and toxins 
• regulating constituents to reduce addictiveness and palatability 
• regulating levels of nicotine with an aim of achieving a zero nicotine level 
in all cigarettes 
• regulating design features, particularly filters. 
 
Where to from here 
 
The tobacco harm reduction forum successfully identified areas of consensus and 
areas requiring further consideration and research. The discussions and findings 
from the forum will be used in determining VicHealth’s work in the area of tobacco 
harm reduction. The expertise shared at the tobacco harm reduction forum by 
members of the tobacco control community and broader health and community 
sectors was invaluable, and VicHealth looks forward to collaborating with these 
groups in considering tobacco harm reduction approaches and research in the 
future. 
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PART I:  
DAY ONE 
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OPENING 
Professor David Hill 
 
I was asked to set the stage with a bit of a view of the history of tobacco control in 
Australia and, in particular, in Victoria. I’d have liked to talk about the people and 
comment on the integrity of those working in the tobacco control area, because I 
think that’s what accounts for the progress we’ve made, but I don’t want to offend 
anyone by leaving them off that list. 
 
I looked back to the 1962 Royal College of Physicians report, and what happened in 
Victoria as a result of that report. Within months of its release every Victorian school 
child received a brochure entitled ‘Shall I smoke?’, which covered the dangers of 
smoking as they were known then. The Cancer Council Victoria, then known as the 
Anti-Cancer Council Victoria, commenced school visits, talking to kids about the 
health risks of smoking. Leading sportspeople such as Murray Rose and footballers 
Alistair Lord and Peter Hudson voluntarily lent their names to anti-tobacco activity 
and the Victorian Health Commission, in that year, was already calling for restrictions 
on the advertising of cigarettes. In 1964 we had the US Surgeon General’s report, a 
complete documentation of what was known about tobacco and its contribution to 
ill-health at that time, and it seemed that the emerging policy issue then was the 
advertising and promotion of tobacco. The tobacco industry came out with a 
voluntary code for advertising which was insubstantial, and not adhered to in any 
case.  
 
In 1967 the Anti-Cancer Council completed a survey of evening television in Victoria. 
University students were paid to watch each of the commercial channels from 6.30 
to 9.30pm, take note of the images broadcast and record the sound, so we had a 
pretty good account of what was going to air. We found that Victorians at that time 
were seeing a television advertisement for tobacco once every eight minutes while 
they were watching TV. So we had some hard data, we had some campaigning 
materials and these generated a lot of news stories. 
 
A second emerging issue soon after that, was in fact harm reduction – discussions 
about the ‘less dangerous’ or, as the tobacco industry liked to prefer to say ‘safer’ 
cigarettes were beginning. The Anti-Cancer Council had the Roswell Park Cancer 
Institute test 12 brands of cigarettes for tar and nicotine content, and published 
those data in Victoria. There was huge interest in that and Nigel Gray got Monash 
University’s Department of Chemistry to start testing Australian cigarette brands 
systematically for tar content or, as the industry called it, ‘total particulate matter’. 
Eventually the Australian government took on the testing of tar and nicotine content 
of Australian cigarettes and regulation required those values to be placed on packs. 
 
Looking back on those events, I’d say it was a ‘false dawn’ in tobacco control. We 
didn’t deliberate sufficiently carefully about the implications of testing cigarettes for 
tar content and taking that information to the public. It would be unkind to say that 
we rushed into it, but I do think that it’s a salutary lesson, because it certainly didn’t 
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advance tobacco control and probably set it back: and that was our work, not the 
industry’s. 
 
In the 1970s, public opinion was, I think, actually ahead of public policy. A Gallup Poll 
in the early seventies showed that 70% of the population favoured reducing or 
banning cigarette advertisements and 79% favoured pack warnings. 
 
In 1971, Nigel Gray went to the Anti-Cancer Council executive committee and asked 
for $50,000 to make some anti-tobacco ads and put them to air. It was a huge 
amount of money at that time, and it’s a great credit to Nigel and the executive 
committee that they were prepared to risk that money. We had enormous fun 
making the 26 ads in two days in an old garage in Fitzroy. John Bevins wrote satirical 
scripts and we had support from very famous actors including Miriam Karlin, Warren 
Mitchell and Fred Parslow to make the ads. We know now, and we pretty well knew 
then, that funny ads don’t convert smokers into non-smokers, but the target 
audience wasn’t the smoker, it was the federal politicians, members of the House of 
Representatives, because we were aiming for a legislated ban on TV cigarette 
advertising.  
 
So we made the ads and went to the TV stations, bought some air time, and said 
we’d like to run these ads. They were first screened privately for ourselves and for 
the managing directors of each of the networks. The response was a mixture of fear 
and apoplexy: we were told that we were saying something nasty about the product 
of another advertiser on the channel, and so we were banned. But in that portfolio 
of 26 ads we had one with Nobel Laureate Macfarlane Burnet talking about what a 
bad thing the TV advertising of cigarettes was for our youth. You can imagine how 
useful it was to be able to accuse the TV channels of banning a Nobel Laureate in 
Medicine from speaking his mind, so we got those ads on air.  
 
Also in the 70s, we started to lay the foundations for a public health response to the 
tobacco problem. The first pack warnings came in 1973 although the industry, in 
redesigning their packaging, were very careful to make them almost invisible. We 
thought it was very important, because it locked government into a ‘smoking is 
harmful’ position, and we could build on that – it had great symbolic importance for 
us. 
 
Around 1973-74 the new Whitlam government moved to phase in a ban on TV 
advertising of tobacco, beginning with a plan over three years to reduce the amount 
and restrict the times during which cigarette advertising could occur. Then, of 
course, came the dismissal, and we were quite concerned that the new government 
wouldn’t be committed to following through on the plan. But the new liberal 
government completed the phase out, and we had the end of broadcast advertising, 
leaving print and sponsorship to deal with.  
 
In 1978 an interesting thing happened. A young man walked into my office who had 
not made an appointment. This young man turned out to be the now Honorable 
Mark Birrell. At the time Mark was the president of the Monash University Young 
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Liberals and was interested in tobacco control. Mark advised that he wanted to put a 
motion up through the Monash Young Liberals to the State Conference of the Liberal 
Party to ban advertising of cigarettes. Mark has been involved in the tobacco control 
game for a long time and is now Chair of VicHealth!  
 
The 1980s was when the real anti-smoking campaigns began in Australia – we had 
the famous NSW ‘Quit for Life’ program, the early campaigns in Western Australia 
and in Victoria. These campaigns, now drawing on behavioural theory, were well-
grounded and very durable – the old ‘sponge’ ad still has impact. Another important 
feature of these campaigns was that the effects began to be measured and we were 
actually starting to pin down the impact of these at a population level. The Quitline 
began to be introduced around the country as a service to smokers to help them 
quit, but also as a research laboratory, and an important one. 
 
In this period, passive smoking became a big issue – new scientific evidence emerged 
regarding the harm of involuntary smoking, and so did public policy responses. 
Again, I think the public were somewhat ahead of the regulation in this area. We had 
workplace bans coming in that grew broader and broader, restaurant bans later, and 
pubs much later again. Notably, we had the tobacco industry contesting the 
evidence of the harm of passive smoking through the courts. 
 
The Victorian Tobacco Act 1986-87 was an example of both opportunism and a 
readiness in public health to grasp an opportunity, and the formation of the 
Victorian Health Promotion Foundation (VicHealth) represented a major turning 
point in the world, as the concept of the hypothecated tobacco tax had not been 
utilised before. 
 
Rotating health pack warnings were introduced in 1987, and the 1990s brought the 
Federal Tobacco Advertising and Promotion Act that that was a major step forward, 
although it left some loopholes allowing tobacco sponsorships that continue to exist. 
 
By the mid-1990s, reductions in smoking rates had stalled, and many were worried 
about this. Carmen Lawrence in the Keating government secured about $17 million 
for an anti-smoking campaign and that survived the subsequent change of 
government, leading to the first national anti-tobacco campaign. We were able to 
create new advertising material using top talent, broadcast it on a significant scale 
and evaluate it very carefully to determine the impact and cost-benefit to show that 
anti-tobacco campaigns were a good public health buy. A 1999 tax hike also helped. 
 
Recent years have been an era in which sound population health time trend data is 
available and being used creatively and effectively to quantify what governments get 
for what they spend (or increase in through tax). Most recently and wonderfully 
we’ve had the plain packaging legislation go through Federal parliament.  
 
The slow progress in reducing tobacco harm is explained more by the opposition of 
the tobacco industry, than the addictive nature of the product itself. So the big 
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question now is what are the remaining pathways through which industry can 
protect or extend its market?  
 
It’s a sobering thought that almost everyone who is now dying of a tobacco-related 
disease could have, or should have, known of the dangers before trying their first 
cigarette. We’ve experienced a lifetime of knowing how bad smoking can be for 
health, and yet still have a significant proportion of the population smoking. We 
know there’s a great deal still to do, and we’ve not done nearly as well as we should 
have. 
 
 
 
 
”The Victorian Tobacco Act 1986-87 was an example of 
both opportunism and a readiness in public health to 
grasp an opportunity, and the formation of the Victorian 
Health Promotion Foundation (VicHealth).” 
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WELCOME 
Ms Jerril Rechter, VicHealth 
 
The tobacco control journey has been an extraordinary one over many decades. The 
numbers reflect certainly the dramatic and challenging journey for many of those in 
the room today, and David Hill’s words provide a timely reminder of the importance 
of relationships – we have to build strong relationships not only with the political 
party in power at a given time, but everyone. 
 
In 21 years, the smoking rate among Victorian adults has more than halved, from 
34% to 13.3% in 2013. These figures are hard won. The number of Victorian lives 
that have been saved as a result of tobacco control is priceless. The days of the ‘in 
your face’ Marlboro man advertisements on major Australian highways, sports 
stadiums and arts organisations are long gone, but have been replaced by the 
increasingly covert tactics of the tobacco industry. In the last four years we have 
seen tobacco companies parade as fictional retail groups in an attempt to influence 
Australian tobacco policy and the sale of dirt-cheap cigarettes, blatantly targeting 
children and socioeconomically disadvantaged communities in an attempt to 
maintain a market for deathly products. Just last month a tobacco company 
complained about being forced to introduce cheaper cigarettes to Australia because 
of rising taxes: they are committed to ensuring that cigarettes are affordable and 
removing price as a motivator for their long-term customers to quit. These tactics 
we’ve come to expect, but as their strategies change we need to adapt to continue 
the decline in smoking rates in Victoria and Australia. We need to keep doing what 
works in the mainstream while continuing to look for ways to influence those groups 
hardest to reach. 
 
VicHealth was established under the Tobacco Act of 1987 and since then, collective 
efforts in partnerships with other organisations including the Cancer Council, Heart 
Foundation and local state and federal governments have played a huge part in the 
dramatic reduction seen in the Victorian smoking rate. It has led to both mainstream 
successes and tremendous achievements in tackling health inequalities. In the 
tobacco control space, VicHealth’s aim is and has always been to reduce the tobacco 
toll, with strategies ranging from buying out tobacco sponsorship in the sports and 
the arts, to being a major funder of the Quit program and funding world-leading 
research in tobacco control. Today VicHealth’s vision and direction is guided by our 
ten-year Action Agenda for Health Promotion. Our ten-year goal is for more 
Victorians to be tobacco-free, with a three-year priority of more people living 
smoke-free, and less harm among resistant smokers. Within that vision, our 
commitment to whole-of-population established tobacco control initiatives is 
paramount. Preventing uptake and supporting people to quit remains VicHealth’s 
primary strategy. 
 
However, we need to constantly evolve. New and innovative approaches should 
continue to be explored. Plain packaging, for example, was a world-first approach, 
introduced into law in 2012. While the debate about plain packaging in the media 
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continues, largely driven by dishonest re-commentary and blatantly biased research 
by the tobacco industry, the results are clear. Figures released by the federal 
treasury last month show that 3.4% fewer cigarettes were sold in last year in 
Australia than in 2012. 
 
To evolve tobacco control in Victoria, tobacco harm reduction is one of the areas 
where further research and discussion is needed. While there is general consensus 
among public health experts and the wider community around tobacco control 
policies in Australia, tobacco harm reduction, on the other hand, remains a point of 
contention. It elicits strong differences of opinion in Australia and indeed, around 
the world. Although harm reduction is not a new concept, its history requires us to 
proceed with extreme caution. Industry continues to use high-profile marketing 
campaigns to recruit new young smokers in countries where these are lawful. The 
most recent campaign, the ‘maybe’ campaign, has been introduced across 50 
countries, and clearly targets young people. This and other campaigns have been 
introduced in contradiction to the industry’s own ethical code, which states that he 
industry will not market its products to minors. 
 
Any discussion around tobacco harm reduction must focus on reducing the harm 
being experienced by those who are addicted to tobacco – who are unwilling or 
unable to quit smoking – and identify opportunities to reduce the harm for these 
people. We all know that quitting is difficult. Addressing the physiological, biological 
and psychological aspects of addiction is incredibly complex, and a one-size-fits-all 
approach may not meet the needs of those who are currently addicted to cigarettes. 
However, a harm reduction approach should only be considered if it complements 
existing approaches, to better support those who have benefitted from existing 
tobacco control policies and initiatives.  
 
Invariably, when we discuss harm reduction in the tobacco context, ENDS come to 
mind. We all know ENDS have arrived in Australia, and although the number of 
people using them is relatively low, it is increasing. Media coverage signifies great 
public interest, and highlights the need to ensure we have the best policy approach. 
This is made all the more complex given it is currently illegal to sell or possess e-
cigarettes containing nicotine in Australia. While they are relatively new in this 
country, ENDS have established a market in the US and Europe, and this forum gives 
us an opportunity to hear about some of our international colleagues’ research and 
policy experiences and reflect on the current and potential policy responses to ENDS 
in Australia. 
 
We are in a unique position: our regulatory framework prohibiting ENDS gives us an 
opportunity to proactively examine them before formulating a policy response: the 
great work of so many in the tobacco control community over so many years has 
afforded us this. 
 
It’s clear from the evidence and international experience that we have a tough 
balancing act to perform. Most importantly, we must protect children and young 
people in whatever policy approach is adopted. Despite the best efforts of the 
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industry, youth smoking rates are at an all-time low, and we have a duty and 
responsibility to ensure this continues.  
 
Many at this forum already have well-formed views on tobacco harm reduction and 
the potential role of ENDS. VicHealth has not yet formulated a formal position on 
either of these topics, as we believe the evidence about the benefits and harms of a 
tobacco harm reduction approach is not clear. This uncertainty is a key reason for 
our decision to facilitate this discussion, which represents an opportunity to meet 
with the tobacco control community and those sectors working with those suffering 
from tobacco-related harm to join us in advancing our collective thinking around the 
future of tobacco control in Australia. We need to better understand the gaps in our 
collective knowledge about the harms, costs and benefits of a tobacco harm 
reduction approach, including ENDS, and set our research agenda in the coming 
period accordingly. To harness this knowledge, we will be establishing an expert 
panel with representation from all of these groups to support us in our work, which 
will be informed in part by the discussion here at this forum. 
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IS HARM REDUCTION NECESSARY TO ELIMINATE  
SMOKING-RELATED HARM? 
Professor Ron Borland, Cancer Council Victoria 
 
Tobacco is a huge problem. One of the real problems in tobacco control is that we’ve 
normalised the problem, accepted that it’s continuing to happen and are prepared 
to work to manage it down rather than implement extraordinary strategies to get rid 
of it. One person is dying every six seconds. While I’m up here talking, over 300 
people will die prematurely in the world as a result of their smoking: one of those 
will be an Australian. Extraordinary efforts are required and we should not be taking 
the current situation as a starting point – this is not an acceptable place to start. 
 
Smoking prevalence has been coming down, essentially in parallel for men and 
women. However, if we look at trends over the last few years, we see that while the 
percentage of ‘never smokers’ is going up, the percentage of ex-smokers has 
remained relatively constant in this century. There are still wide socioeconomic 
disparities, and these are not getting any smaller. We had some remarkable success 
in preventing smoking among kids, but this may be beginning to plateau, and there 
are still unacceptably high levels of smoking in this group. 
 
Quitting is extremely difficult. The average smoker will experience on average one 
unsuccessful attempt to quit per year, and at least one more aborted attempt that 
doesn’t make it to the conventional standard of 24 hours without smoking. It seems 
that the more people want to quit, the more they try, but also, the less likely they 
are to succeed. These are ordinary people who want to quit, but have a limited 
capacity to overcome their addiction. We also understand very little about long-term 
relapse, and need to understand more. 
 
Harm reduction is not just about things like ENDS; it is also about trying to reduce 
the toxicity and appeal of existing cigarettes. Nigel Gray and the Tobacco Regulatory 
Committee of the WHO have put out some excellent documents arguing that it is in 
fact possible to somewhat reduce the toxins in existing cigarettes, but the tobacco 
control movement has been deaf to these reports. These ‘safer’ cigarettes are a 
necessary but small step in reducing toxicity, as so many of the toxins are produced 
by combustion.  
 
We need to move to reduce the attractiveness of smoked tobacco by banning some 
of the additives that increase the allure of some forms of cigarettes, and we need to 
look at cleaner forms of nicotine delivery, alternative delivery systems and, 
especially, at vapourised nicotine. 
 
Harm reduction is possible, and people are using vapourised nicotine products 
around the world, both independently of and despite public health efforts and 
actions. There is now a wide range of products that present low levels of acute risk 
when used as intended. We have established low levels of long-term harm for low-
toxin smokeless nicotine from Swedish data on the use of snus, and the story is very 
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likely to be similar for other new nicotine delivery systems, although the data are not 
yet available. 
 
The Swedish and Norwegian experience with snus has led to a marked reduction in 
tobacco-associated death and disease in men. In American adults, there has been a 
decline in smoked tobacco use over recent years, but either an increase or no 
decrease in the use of smokeless tobacco and a definite increase in the use of 
vapourised nicotine products. There have been similar findings in the UK, where 
there has been a marked increase in the use of vapourised nicotine and a drop in 
smoking prevalence. Among adolescents there have been decreases in smoking rates 
in a number of countries in the context of increased use of vapourised nicotine and, 
again, evidence that there is no immediate negative effect.  
 
 
A science-driven approach 
Evidence is only ever predictive of the future, it does not determine the future. 
Much of the evidence we need for population-based research we can’t have until 
something has been in place for a long time. But science gives us soundly quantified 
theory that has been tested, and has greater predictive capability than mere 
speculation. It’s the theoretical analysis of what’s likely to happen that we should be 
focussing our attention on. 
 
Theories can frame what can be considered as a class, and what requires 
differentiation. Our current tobacco control model, while extremely successful in the 
past, is now narrowing our thinking and limiting our ability to evaluate the potential 
of some new things. 
 
Social contextual theories focus on elimination of smoking and involve de-
normalisation of smoking, environmental change, constraining industry and effective 
communication and incentives. All of these have been done since 1962, mainly in 
Australia since the mid 1980s, and we’re a little over half way to solving the problem. 
But that was the easy half: the hard half is yet to come.  
 
Gaps remain in our current conventional thinking. We underestimate the importance 
of product variation in terms of addictiveness and harmfulness. We have an overly 
simplistic view of people – the extent to which they vary, and the extent to which 
they’re addicted. Some people find smoking so important in their lives that quitting 
is inconceivable. Others can walk away with ease. We misunderstand people’s 
motivations. We are also taking an over-simplistic view of the tobacco industry.  
 
A more appropriate biopsychosocial model attempts to bring more biological 
aspects, more psychological variation into our thinking around tobacco control. It 
accepts that people vary in their desire for nicotine and accepts limits to both human 
rationality and social influence. 
  
For the most addicted, successful quitting is unlikely. We need to think about harm 
reduction in addition to the current agenda. 
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Electronic nicotine delivery systems (ENDS) are designed to be attractive to use, 
unlike conventional nicotine replacement products that were specifically designed to 
be unattractive. Even though it’s not promoted as such, in England more people are 
using ENDS as a cessation aid than approved cessation aids. Electronic cigarettes are 
the best known and most widely disseminated ENDS, but there are others coming 
through with characteristics that should be considered in regulation. Product 
appearance varies, and product types are evolving. 
  
Rates of use of ENDS in countries where they are legally sold are much higher than in 
Australia, but their use here has gone up markedly over the last few years. Around 
6% of Australian smokers and recent ex-smokers are currently using e-cigarettes, 
and 40% of those report using types containing nicotine, even though they are 
technically banned. Surveys have shown that we’ve been extremely successful in 
Australia in confusing the public about the harmfulness of these products. 
 
Theoretically likely effects of vapourised nicotine include its use as a means of no-
longer smoking, either regularly or at all. It is clearly the most popular alternative to 
smoking to date, and at least as effective as NRT. It is likely to be used more as a 
substitute by those unable to maintain abstinence, but how much it is used to quit 
smoking will depend on how it is regulated and promoted. 
 
Uptake of ENDS by adolescents is theoretically likely, and probably correlated with 
uptake by smokers. Some of this uptake is desirable if it replaces smoking – there 
would be a net public health benefit. It is undesirable for those who would not have 
smoked (assuming there are long-term adverse effects), and we should be 
prohibiting sales to minors and greatly restricting advertising. 
 
 
”We’re a little over half way to solving the problem. But 
that was the easy half: the hard half is yet to come.” 
 
 
It is extremely unlikely that these products will become a gateway to smoking. This 
fear assumes a desire to smoke over and above the desire for nicotine. If use of 
vapourised nicotine is seen as a way of not smoking, it is more likely to further de-
normalise smoking than re-normalise it. However, if the population is confused into 
thinking ENDS are as harmful as smoked tobacco, it could lead to re-normalisation of 
smoking.  
  
There is a lot of uncertainty about the future in this area. How patterns of use of 
ENDS will change over time is unknown. In terms of long-term health risks, they are 
almost certainly far less for ENDS than for smoking, but what smaller risks there may 
be we don’t know, and aren’t going to know for decades.  
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We need to take a more sophisticated view of the tobacco industry, who now own 
most of the big vapourised nicotine companies. While industry involvement is a 
major motivator of the tobacco control community’s opposition to vapourised 
nicotine, their agendas and strategies, motivations and business plans require 
detailed analysis.  
 
Critical to this debate is the correlation of risks and benefits of vapourised nicotine. 
The better ENDS are as a replacement for smoking, the more they will encourage 
switching or use as a cessation aid, and the easier it will be to legislatively 
marginalise or ban smoked tobacco products. On the other hand, they may be more 
likely to be attractive to non-smokers and youth, and the larger the black market will 
be if they are banned. 
 
There is a range of regulatory options we may be able to take. Current consumer law 
may be okay for regulating the products (potentially including a maximum nicotine 
level), but is unsuitable for controlling promotion – we need dedicated legislation for 
this purpose.  
  
The Therapeutic Goods Administration has the tools to deal with these products, but 
it would require some sort of fast-tracked approval system, rather than each product 
having to go through a series of randomised controlled trials, which would 
effectively kill the market. This process would, however, be a poor fit if recreational 
use is likely to be a part of the long-term landscape. 
 
Total banning or prescription-only availability are both too restrictive to realise many 
of the potential benefits of ENDS. Limited access (for example through pharmacy) 
may be sensible for bottles of e-liquids, as large volumes of poisonous substances do 
need to be treated carefully. ‘Behind the counter’ access would seem a sensible 
strategy, as totally open access is too likely to result in inappropriate use. The 
enclosed systems, including the cartridge ones, however, should be freely available, 
ideally more so than cigarettes. 
 
Regulation should be designed to: 
• encourage maximal uptake of ENDS by smokers 
• promote the use of ENDS in ways that maximise smoking cessation, even if 
this involves prolonged use 
• encourage innovation to achieve more effective products, at least until ‘the 
job is done’ 
• make smoking less attractive. 
  
Regulation should try to avoid: 
• slowing transitions to these products from smoking 
• mass uptake among those who would not otherwise smoke 
• favouring ‘Big Tobacco’ companies and conditions that support a black 
market. 
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In addition, we need to further regulate smoking, including consideration of banning 
filter venting (perhaps the biggest single thing we could do to reduce the appeal of 
cigarettes) and put vapourised nicotine products on more of an even footing.  
 
We should be banning most additives and exploring the implications of banning 
filters, as there is evidence that these are primarily a reassurance device. We should 
increasingly restrict sales points, which is a missing component of the old agenda, 
and make lower-harm nicotine products available wherever cigarettes are sold.  
  
We are witnessing the emergence of a new set of technologies that require a new 
way of thinking. How we manage it will determine whether we maximise the net 
benefits or miss the opportunity. ANDS are not potent enough to work unassisted, 
and too many people are dying today to delay action. The risks should be 
manageable – we have the collective strategies and skills to manage them, as well as 
the demonstrated capacity to drive smoking down. ENDS represent an opportunity 
to be embraced carefully, thoughtfully and systematically. 
 
 
 
Disclaimer: The views expressed here are my own, and may not reflect those of my 
employer. 
 
 
 
 
”We need to further regulate smoking, including 
consideration of banning filter venting (perhaps the 
biggest single thing we could do to reduce the appeal of 
cigarettes) and put vapourised nicotine products on 
more of an even footing.”  
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ETHICAL ISSUES IN AUSTRALIAN POLICIES TOWARDS ENDS 
Professor Wayne Hall, University of Queensland 
 
What should be the goal of tobacco policy? If it is to eliminate tobacco and nicotine 
use, then there is no role for tobacco harm reduction. If, however, it is to eliminate 
cigarette smoking, then there is a role for harm reduction strategies. 
 
The history of tobacco harm reduction began in the 1950s and 60s, with the failure 
to develop a ‘safer’ cigarette. More recently there has been vociferous and divisive 
debate about smokeless tobacco inspired by the Swedish experience with snus, an 
option ruled out in Australia by a ban on their sale in 1991. This history prompts the 
question: what is different about tobacco harm reduction using ENDS? 
 
As they don’t involve smoke inhalation, ENDS are probably far safer than cigarettes; 
but how much safer is a topic of much debate. E-cigarettes feel more like smoking 
than other delivery systems in terms of nicotine inhalation and physical hand and 
mouth attributes. Perhaps because of this, there is much greater interest from 
smokers in ENDS than in smokeless tobacco, and we have seen very rapid uptake of 
these devices by smokers in the US and UK, alarming many in the tobacco control 
community. 
 
Various claims have been made about ENDS, including that they represent: 
• ‘transformational technology’ that will end smoking, leading to huge public 
health gains  
• a distraction from the tobacco ‘endgame’, undermining significant 
achievements in plain packaging, increased taxation and restrictions on sales 
• a major threat to tobacco control policies, as they may discourage quitting 
via dual use, re-normalise smoking and lead to new, younger smokers being 
recruited. 
 
 
“As they don’t involve smoke inhalation, ENDS are 
probably far safer than cigarettes; but how much safer is 
a topic of much debate.” 
 
 
The population health impact of these products will be difficult to judge without 
letting them into the market. However, ENDS have the potential to end smoking only 
if: 
• most smokers take up ENDS 
• there is little or no dual use of cigarettes 
• there are very few new recruits to smoking. 
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Critics query each of these assumptions, and point to the potential offsetting harms, 
including high rates of dual use among smokers, a re-normalisation of smoking and 
an increase in smoking rates among young adults.  
 
The sale of ENDS has been banned in Australia on the basis of existing poisons 
legislation regarding the sale of nicotine rather than any specific debate about these 
products. Australian users, however, are purchasing e-devices without nicotine, 
buying nicotine over the internet, illegally importing it, or buying it locally regardless 
of the ban. A recent WA court decision effectively bans the sale of e-devices without 
nicotine as well as those containing nicotine in that state. The question remains as to 
whether Australians are committing a criminal offence in using these devices. 
 
In Australia, there is a high level of support in the public health community for the 
ban on ENDS on the basis that tobacco harm reduction strategies put successful 
tobacco control policies at risk, that ENDS will not reduce harm, and that their use 
perpetuates addiction. A minority, however, supports a relaxation of the ban to 
allow some recreational use of these products and research on their public health 
impacts. 
 
The ENDS companies with the largest sales are now owned by ‘Big Tobacco’, another 
source of alarm for the tobacco control community. Many feel that what’s good for 
the industry must, by definition, be bad for public health.  
 
An ethical analysis can clarify competing ethical principles invoked in debates and 
predictions about the consequences of different policies. It can help to identify 
policy compromises that balance competing ethical and social values, provide better 
evidence for future policy decisions and reduce polarisation. Influential ethical 
principles often used in analyses of public health policy are autonomy, non-
maleficence (‘do no harm’), beneficence (public good) and justice. In this case, as in 
many contentious public health issues, there are conflicts between autonomy and 
beneficence that must be resolved through the political process. 
 
From an ethical standpoint, a ban on ENDS is a paternalistic approach that violates 
the autonomy of adults and smokers who are denied access to less harmful nicotine 
products, while still allowing more harmful cigarettes. This disadvantages addicted 
and socially-disadvantaged smokers and those who want to reduce their individual 
risk. 
 
Supporters will say that a ban serves the public good by preventing another harm 
reduction hoax (as seen with light and low tar cigarettes), that dual use will 
discourage quitting, and that the availability of ENDS may lead to the recruitment of 
new smokers.  
 
Opponents of a ban will argue that it prevents smokers from reducing harm, it 
represents a missed opportunity to eliminate cigarette smoking, promotes 
disrespect for the law and encourages a black market: essentially failing to regulate 
ENDS in consumers’ best interests.  
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Options for allowing ENDS range from approving them only for smoking cessation 
(requiring sponsorship from Big Pharma or Big Tobacco), allowing their sale for other 
uses (with regulatory restrictions) or allowing them to compete with cigarettes as a 
recreational product. If open competition with cigarettes is allowed, regulation could 
be used to make ENDS as available as cigarettes are now (levelling up), or to make 
both cigarettes and ENDS less accessible than cigarettes currently are (levelling 
down).  
 
As with most public health debates, the ethical principles and consequences involved 
must be balanced. As the consequences are still unclear, the evidence needed to 
inform the ongoing debate includes: 
• the value of ENDS in smoking cessation 
• the health effects of ENDS 
• uptake of ENDS among young people 
• smoking prevalence among young people 
• the public health impacts of ENDS use.  
 
 
 
 
Options for allowing ENDS range from approving them 
only for smoking cessation (requiring sponsorship from 
Big Pharma or Big Tobacco), allowing their sale for other 
uses (with regulatory restrictions) or allowing them to 
compete with cigarettes as a recreational product.”  
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VISUALISING POSSIBLE SCENARIOS WITH ENDS 
Professor Simon Chapman, University of Sydney 
 
Over a period of 40 years, there have been many hyped-up claims for tobacco harm 
reduction products such as filters, ‘lights’ and ‘milds’, reduced carcinogens and heat 
rods. All have been fraudulent and/or market failures. We need to take a significant 
pause to examine what we’ve learned from this. 
 
Some believe the evidence is in already on ENDS, and we should be opening the 
regulatory floodgates: but I am filled with considerable doubt and indecision, which 
seems an appropriate position to be in at this junction in the history of these 
products.  
 
The vaping industry’s agenda may include no pharmaceutical regulation, allowing 
vaping in all public places, unrestricted advertising, a lack of restriction on ‘kiddie’ 
flavours, high-yield nicotine e-juice and a lack of concern over children taking it up. 
The suggestion that advertising could be restricted to current smokers is similar to 
that made by the tobacco industry regarding cigarettes that has been fought by the 
tobacco control community over past decades. 
 
In the best-case scenario, there may be a mass and rapid migration of smokers to 
ENDS, who use them as a cessation aid and eventually succeed, coupled with 
negligible uptake of ENDS by ex-smokers and never smokers, especially children. 
Longer-term data would show negligible evidence of ENDS being used as a ‘gateway’ 
to smoking. Prolonged, frequent and deep inhalation of nicotine over decades would 
prove to be benign and second-hand exposure to vape assessed as inconsequential 
to health. In this hypothetical utopia, the tobacco industry would experience deep 
erosion of sales and profits from tobacco, voluntarily stop all promotion of tobacco 
and halt its opposition to effective tobacco control. Millions of lives would be saved. 
 
There are reasons to be highly sceptical about most of these claims.  
 
In the worst-case scenario, we might see mass global uptake of ENDS, including by 
many children who would never have used any tobacco product. Smoking cessation 
rates using ENDS would be little different to that seen with current methods. In this 
dystopia, population smoking cessation would stall, with most smokers dual-using 
(cigarettes and e-cigarettes). There would be widespread evidence of would-be 
quitters remaining smokers, and smoking cessation volumes would soon be eclipsed 
by new ENDS user uptake. In addition, there would be a significant drift of new ENDS 
users into smoking as well, so that the net impact on smoking is an increase. ENDS 
advertising and promotion would proliferate, especially in social media, and the 
smoking ‘performance’ would be rapidly re-normalised as all indoor smoke-free 
areas allow vaping. 
 
Same name vape/tobacco products would cross-promote, and, of course, long-term 
use of inhaled nicotine would be confirmed to have an important role in pre-
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cancerous cell biology and heart disease. Falling smoking-related disease rates would 
begin to climb again. 
 
I emphasise that this is a dystopian vision – I don’t believe all of those things would 
happen, but I believe some of them are possible.  
 
So what does the evidence to date suggest about the health risks of vaping 
(including second-hand exposure), its effectiveness in smoking cessation, the 
likelihood of dual use and the health benefits of reduced smoking? What are the 
risks of vaping uptake by non-smoking children? 
 
It’s important to note that no one is arguing that vaping is, or is likely to be, 
anywhere remotely as risky as smoking. But vape is not just water vapour: are there 
health risks associated with prolonged, frequent inhalation of nicotine, fine and 
ultra-fine particles, vapourised flavourants & propylene glycol? 
 
An analysis of 28 liquids from seven manufacturers in Germany found 141 different 
volatile flavour compounds in these products. Glycerol and propylene glycol were 
present in all; however, in addition: 
• ethylene glycol (associated with markedly enhanced toxicological 
hazards) was the dominant compound in five products  
• coumarin, acetamide and formaldehyde were detected in some samples 
• seven out of ten ‘free-of-nicotine’ products contained nicotine. 
 
Although some argue that ENDS are, in public health terms, benign, there is 
emerging evidence that this is far from the case. Recent studies have shed further 
light on the particle constitution of the aerosols inhaled from ENDS, which may not 
be significantly different to those from cigarettes and may or may not be of clinical 
significance. Chemical manufacturers do not recommend glycols in applications 
where breathing or human eye contact with the spray mists of these materials is 
likely. 
 
There is a great deal of evidence about the effect of nicotine itself on physiological 
processes. In animal studies, nicotine deregulates essential biological processes like 
regulation of cell proliferation, apoptosis, migration, invasion, angiogenesis, 
inflammation and cell-mediated immunity in a wide variety of cells. The list of 
cancers reportedly connected to nicotine is expanding and presently includes small-
cell and non-small-cell lung carcinomas, head and neck, gastric, pancreatic, 
gallbladder, liver, colon, breast, cervical, urinary bladder and kidney cancers. 
 
In Sweden, many years of prolonged snus use by men has culminated in little 
evidence of high levels of any smoking-related or other cancers. However, snus 
represent a significantly different exposure pathway to e-cigarettes, and the deep 
inhalation of flavourants and propylene glycol must also be taken into account. A 
large longitudinal study of Swedish construction workers followed from 1971-1992 
found that those who had only ever used the seemingly benign snus had a similar 
hazard ratio for smoking-related cancers as did combustible cigarette smokers. The 
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researchers concluded that “our results concerning snus users seem to narrow in on 
nicotine as a conceivable culprit.” 
 
Many studies on smoking cessation and ENDS have major selection bias problems, 
particularly some online surveys. In the real world, one study showed that although 
ENDS users may be slightly more likely to remain abstinent than those who used NRT 
or no cessation aid, there was a small absolute difference, and 80% of smokers who 
attempted to quit using ENDS still failed. These point-prevalence data give no insight 
into relapses: longitudinal data are desperately needed on the shape of the relapse 
curves for those using NRT, ENDS, varenicline or no aid to quit.  
 
Interestingly, there may not be the expected benefit from smokers reducing their 
level of smoking, with several large, longitudinal studies failing to show any 
improvement in outcomes such as all cancers or premature death. In one study, 
researchers commented that although smoking reduction was associated with a 
significant decrease in the risk of lung cancer, the size of the risk reduction was 
smaller than expected. 
 
 
“Longitudinal data are desperately needed on the shape 
of the relapse curves for those using NRT, ENDS, 
varenicline or no aid to quit.” 
 
 
In terms of uptake, data from Britain in 2013 showed that ENDS use in children was 
primarily among those already smoking. In the US, while the proportion of students 
ever currently using ENDS is small, there is a rapid rate of increase. In Utah, 
researchers found not only a rapid increase in use of ENDS among youth, but also 
that despite having no legal access to them, this group was three times more likely 
than adults to report current use. In addition, nearly one-third of young recent ENDS 
users reported that they had never tried a conventional cigarette.  
 
In Australia, we currently have the lowest rates of smoking among young people 
ever seen, and although these data are only early indicators, the trends seen among 
youth overseas are worth considering in our regulatory stand.  
  
In reality, the large majority of ENDS users continue to smoke cigarettes. Dual use is 
projected in all investment analysts' reports and is exactly what one would expect as 
cigarette companies rapidly take over the ENDS business. There are signs of 
explosive growth in ENDS use, with many kids initiating nicotine addiction with these 
devices. In the US, marketing is ‘back’ on TV and radio, and product placement in 
movies and TV is going wild. Meanwhile, the tobacco control community is spending 
lots of time arguing with each other. 
 
ENDS may hold significant, game-changing promise for both cessation and harm 
reduction, and there is current rapid growth in use and consumer interest. However, 
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they also hold the potential to be a ‘weapon of mass distraction’ that may stall 
smoking cessation in the population, re-normalise the smoking performance and 
draw attention away from the challenges of implementing known effective 
strategies. 
 
We urgently need quality, longitudinal evidence that cannot be collected while these 
products are banned. If the promise of ENDS is delivered, our focus should be on 
regulating for access for smokers while minimising the risk of holding smokers in 
smoking and introducing children to addiction. 
 
 
 
“In Australia, we currently have the lowest rates of 
smoking among young people ever seen, and although 
these data are only early indicators, the trends seen 
among youth overseas are worth considering in our 
regulatory stand. “ 
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ENDS: EVOLUTION, HEALTH EFFECTS, CESSATION AND DUAL USE   
Associate Professor Chris Bullen, National Institute for Health Innovation 
 
The World Health Organization defines ENDS as “devices whose function is to 
vapourise and deliver to the lungs of the user a chemical mixture typically composed 
of nicotine, propylene glycol and other chemicals, although some products claim to 
contain no nicotine. A number of ENDS are offered in flavours that can be 
particularly attractive to adolescents.” Electronic cigarettes (e-cigarettes) are the 
most common prototype of ENDS, including disposable and rechargeable, pen-style 
and tank varieties. 
 
While the idea of a cigarette substitute is not a new one, there has been recent rapid 
evolution in technologies delivering nicotine for inhalation including: 
• VOKE, based on asthma MDI technology  
• Nicotine pyruvate technology – utilising a chemical reaction between 
nicotine acid and base that produces inhalable nicotine pyruvate vapour.  
 
ENDS consumption may surpass combustible cigarette sales within a decade, and 
forecasts suggest that the profitability of combustible cigarettes will decline from the 
present onwards.  
 
There is no evidence that ENDS use in the short term poses serious risks to health: 
they are almost certainly safer than tobacco smoking. It has been reported that 
there are no changes in blood pressure after four weeks of use and no changes in 
blood count. Known effects include transient mouth and throat irritation and dry 
cough, acute lung function changes following brief use (comparable to those 
experienced by tobacco users) and acute, clinically insignificant increases in airways 
resistance following use. 
 
Among different ENDS products there is varying accuracy of labelling of nicotine and 
other contents, and there is variable reliability of operation and degree to which 
different brands and different cartridges within the same brand expose users to 
nicotine and other compounds.  
 
While tobacco-specific N-nitrosamines and polycyclic aromatic hydrocarbons are 
present in very low levels in solution (similar to the levels found in NRT) and 
formaldehyde and acetaldehyde have been detected in very low levels in ENDS 
vapour, there is no evidence that these products expose users to concentrations of 
toxins sufficient to cause harm. 
 
There are only two published cessation randomised controlled trials that included 
adverse effects as well as efficacy data – ECLAT and ASCEND. ECLAT, comparing 
ENDS ranging in nicotine dose from 0-7.2 mg, found no difference in the frequency 
of side effects between groups, and they declined over time. In ASCEND, comparing 
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an NRT patch with a 21 mg ENDS and a 0 mg e-cigarette, similar event rates for all 
adverse effects were seen in each group. 
 
Other forms of research on ENDS and smoking cessation involve: 
• internet-based user surveys   
• smokers’ panels  
• Quitline callers  
• population surveys 
• case series 
• nicotine delivery and withdrawal studies  
• confidence/readiness to quit studies. 
 
 
“Among different ENDS products there is varying 
accuracy of labelling of nicotine and other contents, and 
there is variable reliability of operation and degree to 
which different brands and different cartridges within 
the same brand expose users to nicotine and other 
compounds.” 
 
 
 
While device characteristics and user experience heavily influence nicotine delivery, 
ENDS aerosols do have particle diameters and concentrations comparable to 
tobacco smoke, which may penetrate deep into the respiratory tract. Early studies in 
novice users found that nicotine delivery was lower and slower than with cigarettes, 
comparable with a pharmaceutical nicotine inhaler. However, there is a suggestion 
that newer products used by experienced ‘vapers’ can deliver physiologically active 
amounts of nicotine. 
  
The evidence on cessation efficacy from ECLAT and ASCEND suggests that in smokers 
who use ENDS for 12-13 weeks with little to no behavioural support, six month quit 
rates appear to be modest, of similar quitting effectiveness to nicotine patches when 
used with minimal behavioural support and similar for both nicotine-containing and 
nicotine-free e-cigarettes. These trials showed e-cigarettes may lead to reduced 
cigarette consumption and nicotine e-cigarettes delay relapse back to regular 
smoking. While mild, self-limiting side effects are reported, e-cigarettes are highly 
acceptable to users, more so than NRT. 
   
From the UK research experience, it appears that use by never smokers is extremely 
rare – ENDS do not appear to be ‘re-normalising’ smoking. They are also not 
undermining smokers’ motivation to quit or the ongoing decline in smoking 
prevalence, and they may be contributing to a reduction in smoking prevalence 
through increased quitting success. 
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In the US, there is evidence that 11.5% of current smokers are using ENDS every day. 
The natural history of ENDS use over time is characterised by substantial reductions 
in cigarette use, reductions in daily nicotine intake and progression to a lower level 
of overall nicotine addiction. 
 
Therefore mass uptake has the potential for large population health impact even if 
there is only a modest cessation effect, and if newer models are more effective than 
those tested in the randomised controlled trials to date.  
 
ENDS represent both promise and peril to the tobacco control community. The 
promise relates to the possibility of genuine tobacco harm reduction and a 
breakthrough for smokers and tobacco control. The peril involves the possibility of 
fewer smokers becoming completely abstinent, the recruitment of new addicts and 
reinvigoration of the tobacco industry. 
 
 
 
 
Disclosures 
I was Principal Investigator of the ASCEND trial, a study funded in full by the Health Research Council 
of NZ. I have received benefit in-kind from a manufacturer of smoking cessation medications but I 
have not received any benefits from the manufacturers/retailers of ENDS/ANDS nor the tobacco 
industry. 
 
 
 
”Mass uptake has the potential for large population 
health impact even if there is only a modest cessation 
effect, and if newer models are more effective than 
those tested in the randomised controlled trials to date.” 
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AN ECONONOMIC EVALUATION OF TOBACCO HARM REDUCTION –  
A RESEARCH PROPOSAL  
Dr Coral Gartner, University of Queensland 
 
Harm reduction is a widely-supported approach in the substance use field that 
includes interventions, programs and policies that seek to reduce the health, social 
and economic harms of substance use to individuals, communities and societies. 
There is a focus on the prevention of drug-related harm rather than the prevention 
of drug use per se. 
  
A number of examples exist, including the use of random breath testing and 
volumetric taxation in alcohol control, methadone substitution therapy and needle 
exchange programs in injectable illicit drug initiatives, and legalisation of cannabis in 
parts of the US and Uruguay. 
 
Harm reduction is one of the three pillars described in the National Tobacco 
Strategy, along with the reduction of demand and supply, although there are few 
concrete examples of harm reduction approaches given. Regarding ANDS, the 
Strategy specifically states there is a need to better understand the potential risks 
and/or benefits, determine whether there is a need to increase restrictions on their 
availability and use, and identify the most appropriate policy approach for Australia. 
 
Economic evaluation can provide a comparative analysis of alternative courses of 
action in terms of both their costs and consequences, and such evaluations are 
increasingly important to policy makers. Opportunity costs must be identified to 
ensure the most benefit from the scarce resources available. Some types of 
economic evaluations consider only costs (e.g. cost-of-illness studies, cost analyses 
for intervention costs), while others (cost-effectiveness, cost-utility, or cost-benefit 
analyses) seek to balance costs and benefits.  
 
 
”Economic evaluation can provide a comparative analysis of 
alternative courses of action in terms of both their costs and 
consequences, and such evaluations are increasingly important 
to policy makers.” 
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Some examples of various types of economic evaluations in the tobacco context 
include the following: 
 
Collins’ and Lapsley’s studies of the social costs of smoking 
These used a ‘costs only’ approach to compare the actual population size and 
structure in the specified year with a hypothetical alternative population with 
no past or current smoking. The costs of past and present smoking were 
estimated for the specified year only – future and past costs were ignored. 
 
The tangible costs identified in this study included lost productive capacity 
due to premature death or smoking-associated illness, health care for 
smoking-associated illness, fires attributable to smoking and the cost of 
consumption. Intangible costs included the psychological costs of premature 
death (incurred by family and friends) and the loss of enjoyment of life 
(incurred by the smoker) as a consequence of smoking-associated illness.  
 
On average, the intangible value of one year of life was valued at $53,267 in 
2004–05 prices. The total social costs of tobacco in 2004/05 were modelled 
to be $31,485.9 million. 
 
Quit Benefit Model (QBM) 
The Quit Benefit Model calculates tobacco-related disease avoided, life-years 
gained, quality-adjusted life-years and health care costs associated with 
quitting with a time horizon of ten years. Results are reported for simulated 
cohorts of 1,000 quitters. This model calculates costs from the perspective of 
the healthcare system, including hospitalisations, revascularisation 
procedures, drugs, health professionals’ services and terminal care. It does 
not include productivity costs and second-hand smoke exposure impacts. 
 
Cost effectiveness of NRT as a short-term cessation aid 
Bertram et al. examined the cost-effectiveness of NRT as a short-term 
cessation aid using: 
 a health system perspective (cost to PBS) 
 cost per DALY averted  
 a time horizon of the smoker’s lifetime  
 the population of current smokers, motivated to quit, in the baseline 
year (2000). 
 
The interventions modelled were NRT, bupropion, and bupropion (as first-
line treatment) and NRT (as second-line). 
 
Benefits of Smoking Cessation on Outcomes (BENESCO) 
A similar model to that used by Bertram et al. is the BENESCO model, a cost-
utility analysis using the Markov model and adopting the perspective of the 
health care system. 
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Different time horizons were examined, including lifetime as well as one, five, 
ten and twenty years, and the model was primarily used to compare 
varenicline with products that were already available on the market 
(bupropion, NRT and unaided cessation). 
 
NICE economic modelling of tobacco harm reduction 
The National Institute for Health and Care Excellence in the UK used 
economic modelling of tobacco harm reduction to inform their guidelines on 
the topic. This modelling included the perspectives of the health system, the 
individual and wider society using time horizons of a person’s lifetime as well 
as one, three and five years. It considered medicinal NRT in terms of quitting, 
long-term substitution, reduction in tobacco use and temporary abstinence. 
 
This evaluation did not support temporary abstinence, but all other options 
were found to be cost-effective. However, it was concluded that harm 
reduction approaches were not as cost-effective as smoking cessation 
approaches. 
 
 
Our proposed economic evaluation of tobacco harm reduction 
 
Tobacco harm reduction options include medicinal nicotine products (gum, lozenges, 
inhalator etc), recreational nicotine products (ENDS and other non-medicinal 
products) and low-nitrosamine smokeless tobacco (e.g. Swedish snus), but we will 
focus on ENDS as being most applicable to the current Australian context. 
 
Our proposed methodology utilises the Markov model to simulate hypothetical 
cohorts of current, former and never smokers until death. It could be built using 
TreeAge Pro software and draw from the BENESCO, QBM and Bertram models. 
 
We will aim to look at multiple perspectives (health system, individual and/or 
society) over multiple time horizons (short-term, medium-term, long-term, lifetime). 
Tangible costs are likely to include treatment of disease, cost of products, costs of 
living longer and productivity costs. Intangible costs and benefits, including factors 
(such as the psychological costs of premature death incurred by family and friends, 
loss of enjoyment of life incurred by the smoker, and even the enjoyment gained 
from the use of cigarettes or ENDS) are far more complex and challenging to 
estimate. Therefore, we will not be including these in our economic evaluation. 
 
The potential adverse effects of ENDS should also be considered, including the 
potential for dual use to delay or deter quitting, use by young non-smokers, 
potential gateway effects, accidental poisonings, and the public use of ENDS 
resulting in the normalisation of vaping and/or re-normalisation of smoking. 
 
We also want to examine potential policy impacts within our model. In terms of 
availability, policy options range from a ban (with associated black market use), 
subsidised or unsubsidised prescription-only access, approval as an over-the-counter 
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medicine, or availability as a general consumer good (using data from the US and 
UK). In terms of price, there is some evidence around the effectiveness of tax 
increases in deterring smokers that could be drawn on.  
 
The intended outcomes of this research include identifying if there are patterns of 
ENDS use that would achieve a net public health benefit, taking into consideration 
potential harms. This includes examination of the burden of death and disease 
avoided or incurred under various assumptions, direct health care costs of those 
diseases, the costs of ENDS and cigarettes as well as social costs. 
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THE WORLD HEALTH ORGANIZATION & ENDS 
Dr Carmen Audera-Lopez, World Health Organization 
 
The World Health Organization (WHO) is concerned about ENDS because they have 
invaded the market, many of them without adequate manufacturers’ quality control 
and disclosure of contents. 
 
As ENDS do not generate the smoke that is associated with the combustion of 
tobacco these products are believed to be safer than smoking tobacco. However, 
ENDS are not innocuous. They contain nicotine (in most cases) as well as other toxic 
substances so their use by the general population, especially by those not addicted 
to nicotine, should not be encouraged. 
 
ENDS are being marketed as effective smoking cessation aids, but there is 
inconclusive evidence that they are more efficient than other approved smoking 
cessation aids such as nicotine gum and patches. 
 
Nicotine addiction is a world-wide problem. Article 5.2b of the WHO FCTC 
encourages actions that reduce tobacco consumption and exposure to second-hand 
smoke as well as prevent and reduce nicotine addiction. Smokers will obtain 
maximum health benefits if they quit completely both tobacco and nicotine use, and 
this is our aim. 
 
In many countries around the world, there are currently no restrictions on the sale of 
ENDS, and they can be sold to minors. ENDS manufacturers are clearly making 
products that are attractive to non-smokers and young people by adding different 
flavours to their e-juices.  
 
Ex-smokers are also being targeted, as in many countries it is permitted to vape in 
places where smoking is not allowed. These circumstances interfere with progress in 
smoke-free policies that de-normalise smoking, reduce the incentive to quit and 
ignore the unknown effect of non-vapers breathing in second-hand vapours. 
 
 
 
”Smokers will obtain maximum health benefits if they 
quit completely both tobacco and nicotine use, and this 
is our aim.”  
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ENDS represent a new area of business for the Big Tobacco companies, but the key 
public health questions remain concerning the health risks to users and others 
exposed to vapours, the efficacy of ENDS as an aid to smoking cessation and 
overcoming nicotine addiction and the extent and effects of their interference with 
existing tobacco control efforts and the implementation of the WHO FCTC. 
 
In 2012, the FCTC secretariat presented a report on ‘Electronic nicotine delivery 
systems, including electronic cigarettes’ at the COP5 conference, encouraging 
countries to regulate these new products. During that conference, WHO was 
formally invited to gather existing research, expose research gaps, and identify 
research areas that need to be focused upon as well as identify options for the 
control of ENDS and examine the evidence on health impacts of ENDS use. WHO has 
developed a background paper covering these issues to present to COP6 later this 
year. 
 
Earlier this year, the 7th meeting of the WHO Study Group on Tobacco Product 
Regulation (TobReg) discussed the regulatory framework and came up with 
recommendations regarding: 
• ENDS design, contents, emissions, capping the dose of nicotine 
• flavours and child-proof caps 
• a minimum age of purchase (18) 
• labelling, including warning of the consequences of ENDS use 
• use in smoke-free environments 
• advertising, promotion, and sponsorship 
• monitoring use. 
  
In the WHO Tobacco Products Survey for COP6, which included items on ENDS, 90 
countries responded, representing 77% of the world’s population. More than one 
third (38%) of the countries where ENDS were available had an advertising ban on 
the products. There was significant variation in how these products (both with and 
without nicotine) were regulated, as consumer products, as therapeutic products 
and as tobacco products. 
 
In 2014, consultation was held with regulatory agencies and experts. This 
consultation identified the need to regulate ENDS in a manner that reduces the risk 
of individual and population health harm, but also allows for the possibility that 
ENDS have the potential to reduce smoking-attributable disease. Priority areas for 
regulation included minimum and consistent product standards, restrictions on 
access for minors, advertising restrictions (especially in regard to health claims), and 
a ban on use of ENDS in smoke-free and enclosed public places. The WHO has also 
conducted a study examining marketing strategies for ENDS in new media, including 
discussion forums and blogs. 
 
Two products are in preparation for presentation at COP6: an update and a 
background paper that will become a chapter in the 5th technical report series and 
presented to the January 2015 WHO Executive Board 136th session. 
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WHO believes that there is an urgent need to regulate these products at least with 
respect to: 
• manufacture and product design 
• sales, imports and exports 
• sales to minors 
• advertising, promotion and sponsorship 
• health claims 
• labelling and health warnings 
• product disclosure 
• use in smoke-free places  
• protection from vested industry interests. 
 
In general, the objectives of regulation are to impede ENDS promotion to and uptake 
by non-smokers, pregnant women and youth, minimise potential health risks to 
ENDS users and non-users and prohibit unproven health claims about ENDS. It 
should also aim to protect existing tobacco control efforts from commercial and 
other vested interests of the tobacco industry. 
 
Parties will need to consider the available national regulatory frameworks that could 
best provide solid regulatory grounds. However it is likely that a two-pronged 
regulatory strategy – regulating ENDS as both a tobacco product, in accordance with 
the provisions of the WHO FCTC, and a medical product – would be necessary. 
 
The WHO is currently reviewing the existing evidence around ENDS and preparing a 
paper for submission to the meeting of the Parties of the WHO Framework 
Convention on Tobacco Control, which occurs in October 2014 
(http://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_10Rev1-en.pdf). 
 
 
 
”It is likely that a two-pronged regulatory strategy – 
regulating ENDS as both a tobacco product, in 
accordance with the provisions of the WHO FCTC, and a 
medical product – would be necessary.”  
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PART II:  
DAY TWO  
  
 41 
 
WELCOME 
Mr Peter Gordon 
 
Peter Gordon briefed in the audience on the day’s presentations and gave a stirring 
background to his longstanding contribution to reducing tobacco harms through his 
litigation practice. 
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THE UK EXPERIENCE OF ENDS 
Dr Alex Gyani, Behavioural Insights Team – UK Government 
 
The role of policy makers is to aggregate the evidence and make policy decisions 
based on that. The current debate on ENDS is based on varying levels of evidence 
from editorials and expert opinion, case series and case reports, cohort studies and 
case-control studies and a small number of randomised controlled trials (RCTs).  
 
A Google search highlights the difficulty that policymakers face in evaluating the 
existing evidence on ENDS. The first search result links to a webpage designed for 
clinicians and sufferers of pulmonary diseases. This references Chris Bullen’s RCTs 
and concludes that ENDS are effective cessation aids. The second ‘hit’ takes quite a 
different interpretation of the same evidence, showing that even high-quality 
evidence can be coloured by interpretation. This difference in interpretation of the 
same evidence explains the differences between the policy debate in the UK and 
Australia. 
 
There are differences between the levels of smoking in the UK and Australia. In the 
prevalence of smoking is now below 20% for first time in 80 years, whereas in 
Victoria prevalence is now at 13%. In the UK, there are socioeconomic inequalities 
with regards to smoking prevalence, much like Australia. For example, in 2012, 14% 
of adults in managerial and professional occupations smoked compared with 33% in 
routine and manual occupations, and the majority of current smokers would like to 
stop smoking. Every year, over 100,000 smokers in the UK die from smoking-related 
causes. However, in the UK we have 2.1 million ENDS users. 
 
Historically in the UK, NRT was licensed for smoking cessation only. In 2009 ‘harm 
reduction’ was approved as an indication for Nicorette inhalers, and it was suggested 
that this indication should be extended to other nicotine-containing products. It was 
felt that NRT should compete on price and the public should be educated about 
relative safety. In 2010 a government white paper recommended all nicotine-
containing products and nicotine delivery systems be regulated consistently to meet 
safety, quality and efficacy standards. A public consultation was announced, but the 
government maintained that no nicotine-containing product or nicotine delivery 
systems could be marketed in a way that promoted or encouraged tobacco use. The 
regulatory approach was developed in consultation with a large range of 
stakeholders, including ENDS manufacturers (although this was before Big Tobacco 
moved significantly into the ENDS space) and documented in a 2011 white paper. 
 
At the same time, there was little political appetite for increasing regulation, 
highlighted by an initiative called the ‘red tape challenge’ that aimed to remove 
regulation wherever possible. While there was careful consideration of the evidence 
around the dangers of ENDS, it was felt that there was no additional harm in current 
smokers using them, and a ‘watching brief’ was adopted to monitor if there was any 
increased harm to those who had not previously been smokers. Furthermore, the EU 
had yet to take a public stance, so the meaning and consequences of ‘light touch’ 
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regulation for ENDS was discussed by opinion leaders and policymakers before a 
clear decision was made on how to regulate them. 
 
ENDS are currently marketed under general product safety regulations that do not 
impose specific standards of purity or efficacy. They do control advertising through 
voluntary codes of practice but deal with breaches reactively, rather than 
proactively. Importantly, they allow indoor use of these products. 
  
From 2015, ENDS will be ‘medicines by function’ and required to have manufacturing 
standards and proactive controls on advertising. However, any nicotine delivery 
device that is deemed a substitute or a cessation aid will receive a preferential VAT 
rate and will be prescribable, making them cheaper than cigarettes. 
 
In the EU, the Tobacco Products Directive will regulate ENDS containing less than 20 
mg/mL nicotine, although the exact science informing this threshold is unclear. 
Products under this threshold will not be available on prescription, and be widely 
available (so they can be clear substitutes). There will be domestic discretion over 
advertising (although cross-border advertising will be banned) and health claims 
cannot be made – packaging will have warnings instead.  
 
Products over the 20 mg/mL threshold will remain subject to Medicines and 
Healthcare products Regulatory Agency (MHRA) licencing in the UK: they will be 
available on prescription, advertising will be allowed (with flavours requiring 
authorisation) and health claims can be made. 
 
While the evidence is being gathered, surveillance of the use of ENDS is of vital 
importance. This will allow us to see whether initial concerns around re-
normalisation and use among non-smokers are valid. For ex-smokers, the number of 
people who have ever used ENDS is increasing to about 12% but the proportion 
currently using them is markedly lower.  
 
 
“While the evidence is being gathered, surveillance of 
the use of ENDS is of vital importance. This will allow us 
to see whether initial concerns around re-normalisation 
and use among non-smokers are valid.” 
 
 
The data also show the growth in prevalence of ENDS users appears to have stalled. 
The use of these products by never smokers appears to be negligible, and similar to 
NRT use, and the prevalence of ENDS use appears to be similar across most age 
categories. The argument of dual use is at the forefront of many people’s minds, and 
there is evidence from the UK that the large majority of ENDS users do also smoke, 
although the total per capita use of nicotine seems to be slowly decreasing and it is 
not known whether dual users would otherwise have used tobacco cigarettes. 
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Public Health England has recently published a paper that summarises current 
thinking to e ENDS regulation, with the ultimate aim of maximising the potential 
benefits of these products while minimising potential harm. 
 
 
 
Disclaimer: Views do not necessarily represent those of the British Government 
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US EXPERIENCE WITH HARM REDUCTION, ANDS & ENDS 
Professor Dorothy Hatsukami, University of Minnesota 
 
The debates currently being held in the US are very similar to those being discussed 
at this forum and centre around defining the goals for public health, which might 
include: 
• ending cigarette use 
• ending use of the most harmful products while reducing the harm of 
remaining products 
• ending the use of all tobacco products 
• ending the use of all nicotine products. 
 
One of the main conclusions of the 2014 Surgeon General’s report was that “the 
burden of death and disease from tobacco use in the United States is 
overwhelmingly caused by cigarettes and other combusted tobacco products; rapid 
elimination of their use will dramatically reduce this burden”. 
 
Proponents of a harm reduction model believe that the primary goal is to eliminate 
the use of combustible products. If tobacco product users are unable to quit using all 
combustible tobacco products, then switching these smokers to noncombustible 
products would contribute to significant reduction in death and disease if the 
benefits outweigh the risks, i.e. if: 
• non-combustible tobacco products, used alone, are far less dangerous to 
individual users than continued smoking 
• non-combustible products would be adopted as a complete substitute for 
smoking by significant number of current smokers, but would not increase 
use among youth 
• smokers who switch to noncombustible products would have otherwise 
continued to smoke (as opposed to quitting).   
 
Currently the product that is the most harmful and addictive (combustible tobacco) 
has the highest rate of use, whereas less harmful and less addictive products 
available are not widely used. The goal then is to push the combustible product 
users to quit or, if they cannot quit, then to less toxic products with less abuse 
potential.  We can achieve this goal by continued comprehensive tobacco control 
measures to prevent and stop all tobacco use, differential taxation and education 
around relative risk. Product standards are currently being examined by public 
health researchers in the US, including reducing the addictiveness and appeal of 
these combustible tobacco products.  
 
In the US in the past decade or so, there has been an explosion of tobacco products 
marketed, ranging from various combustible and non-combustible products. Also 
there are now nicotine-only products such as ENDS, tobacco company-manufactured 
nicotine rubber-like lozenges, and nicotine gum approved to aid cessation. 
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The FDA Family Smoking Prevention and Tobacco Control Act has jurisdiction over 
cigarettes and cigarette tobacco, ‘roll your own’ and smokeless tobacco, and there is 
a proposal currently seeking public comment to extend this to cover cigars, pipe, 
hookah and dissolvable tobacco, ENDS and nicotine gels. 
 
 
”Currently the product that is the most harmful and 
addictive (combustible tobacco) has the highest rate of 
use, whereas less harmful and less addictive products 
available are not widely used.” 
 
 
We have products such as snus and dissolvable tobacco that are sold as substitutes 
for smoking, and hundreds of brands of e-cigarettes, with many different types, 
designs and flavours.   
 
Although the overall rate of ENDS use is low, with about 2% reporting some or 
everyday use, their use has exceeded snus and dissolvable products that have been 
on the market for a longer period of time.  
 
Among adults, we see a significant increase in the use of these products even within 
just a year. The population of adults who are using the products tend to be current 
smokers, with some former smokers and very few never smokers using them.  
 
Among adolescents, we have also seen an increase in proportions of those who have 
ever used and used within the past 30 days. Again, the majority of youth who are 
using these products tend to be smokers, with 80.5% of those who had used ENDS 
within the last 30 days also smoking conventional cigarettes. 
 
It is projected that over time revenues from conventional cigarettes will decrease 
and the sales from ENDS will increase. In the U.S., because limited regulations exist, 
the situation has been described as a ‘wild west.’ 
 
We have no product standards, including no minimum or maximum for nicotine or 
maximums for other constituents. We have no warning labels, no advertising 
restrictions, limited indoor air regulations and limited regulations on sales to minors. 
ENDS can be bought in gas stations, Costco, drug stores, tobacco shops, through the 
internet and at specialised ‘vapour shops’. 
  
We also see an increase in advertising and exposure of these products in magazines, 
on youtube, on TV and in the movies. Messages associated with these 
advertisements are ones of health, smoking cessation, lifestyle improvement and 
defiance. Although there is a ban on billboard advertising for cigarettes, we now see 
billboard advertising for ENDS and, in places where there has been a ban on 
smoking, we now see vaping. 
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There is tremendous consumer support and advocacy for ENDS. Several major cities 
have ‘vapefests’, where people come together to share their experiences and learn 
about new devices or how to maximise the use of their own devices.  
  
In terms of regulatory scrutiny, the FDA blocked importation of ENDS in 2008 as 
unapproved drug delivery systems. Subsequently, shipments of Sottera Incorporated 
e-cigarettes were seized. Sottera argued that these products serve the same purpose 
as cigarettes – that they were a recreational rather than a therapeutic device, and 
the court ruled in their favour, stating that the FDA should regulate these products 
under the Family Prevention and Tobacco Control Act, unless therapeutic claims are 
made. 
 
In April 2014, the FDA released a proposal to give it authority to regulate the 
manufacturing, distribution, and marketing of ENDS. The proposal would prohibit 
sales to minors, distribution of free samples, and sales through vending machines 
except in adults-only facilities. It would also require ENDS manufacturers to: 
• register with the FDA and report all product and ingredient listings, including 
harmful and potential harmful components 
• only market new tobacco products after FDA review 
• only make direct and implied claims of reduced risk if the FDA confirms that 
scientific evidence supports the claim and that reduced risk product 
marketing will benefit public health as a whole 
• include a health warning on packaging and advertising 
• meet FDA standards. 
 
The proposal would not, however, prohibit the sale of flavoured ENDS, restrict 
advertising, marketing, or promotion of ENDS, impose taxes on the products or 
impose restrictions on indoor use. 
  
Currently in some local jurisdictions in the US, greater restrictions and regulations 
have been implemented including bans on sales to minors and distribution of free 
samples, restrictions on use in public places, sale and distribution restrictions and 
taxation measures. Some have attempted to restrict point of sale displays and other 
forms of advertisement, but this has failed. 
 
The American Medical Association and other organisations have also suggested: 
• prohibition of unsupported marketing claims as a tobacco cessation tool 
• avoidance of marketing or other communications that attempt to dissuade 
smokers from quitting smoking completely or from using evidence-based 
methods for cessation 
• requirements for marketing to be aimed at complete substitution for 
cigarettes and not encouraging dual use 
• restriction of advertising and marketing practices that appeals to youth. 
 
A workgroup for the Society for Research on Nicotine and Tobacco came up with 
principles for tobacco harm reduction – before the ENDS debate began – that are 
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pertinent to this discussion. These principles stated that the purpose of the approach 
must be to reduce the death and disease caused by tobacco, with the long-term goal 
of leaving smokers both tobacco- and nicotine-free. The approach should pose no 
additional safety risk, and safety data should be extensive, including data on 
extended use. The approach should not worsen the individual’s level of nicotine 
dependence, and should not reduce the likelihood of eventual cessation of tobacco 
use. Finally, it should not lead to increased population prevalence of tobacco 
dependence or increase the risk of adolescent misuse or abuse, and any promotion 
or marketing efforts of this approach should provide consistent smoking cessation 
messages and offer help in quitting smoking as well as help in terminating use of the 
product. 
 
It is the responsibility of public health professionals to be open-minded about the 
possibility that reduced-exposure products may potentially reduce death and 
disease. It is also imperative, however, that we ensure that the proper regulatory 
system and review is established and that a comprehensive research strategy is 
implemented to ensure the public’s health. 
  
 
 
 
 
 
“It is the responsibility of public health professionals to 
be open-minded about the possibility that reduced-
exposure products may potentially reduce death and 
disease.” 
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THE ENDS OF THE WORLD? RESEARCH, REGULATION AND DEBATE ON 
ENDS AND TOBACCO HARM REDUCTION IN NEW ZEALAND 
Associate Professor Chris Bullen, National Institute for Health Innovation 
 
Smoking prevalence in New Zealand is much higher among Māori populations  
(and, unusually, higher among Māori women than men) than European and other 
populations, with Pacific populations in between and prevalence in Asian 
populations lower (potentially a ‘healthy migrant’ effect). 
 
Tobacco control discourse in New Zealand is dominated by the national goal of 
becoming a ‘smoke-free nation’ (smoking prevalence of less than 5%) by 2025, and 
determination to ensure marked ethnic inequalities in smoking prevalence are 
eliminated. This goal requires a five-fold increase in cessation rates, accompanied by 
halving of initiation rates every ten years.  
 
There has been success with lowering initiation rates: we have dropped below the 
‘business as usual’ forecast already. Between 2000 and 2010, daily smoking rates 
among early teens have dropped from about 15% to about 5%. Strategies to increase 
cessation rates have included: 
• tobacco price rises year on year 
• removing duty free exemption 
• smoke-free environments legislation 
• sector-wide smoking cessation program implementation  
• expanded Quitline services (e.g. SMS) 
• mass media communications 
• innovation funding for community ‘grassroots’ initiatives and innovation 
research funding. 
 
Product regulation, alternatives to smoking and harm reduction strategies are other 
possible approaches. There has been very little funding available to understand the 
role of tobacco harm reduction. However, New Zealand’s research on ENDS has 
contributed to the global knowledge base through research on tobacco product 
regulation and survey data analysis. 
 
A New Zealand adult smokers and recent quitters survey from 2011 showed that the 
proportion of those having ever used ENDS was about 7%. About one third of ever 
users believed they were safer than cigarettes, and a similar proportion that they 
could help people quit. More than half would use them as a cessation aid, and about 
40% (particularly lower-income respondents) said they would swap to ENDS if they 
were cheaper than cigarettes. 
 
The repeated survey in 2013 showed that about one third reported having ever used 
ENDS; about a fifth in the past two weeks, and very few used them daily. Just under 
half who had recently tried to quit smoking had used ENDS, two thirds said these 
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products were for people who want to quit, and a high proportion fsaid they were 
for those who want to cut down their cigarette consumption.    
 
A survey of a nationally-representative sample of Year 10 students in 2012 found 
that 7% had tried ENDS. More than one third of those who identified as current 
smokers had tried ENDS and, of these, no significant differences were found in the 
likelihood of wanting to quit, attempting to quit, or thinking that they could quit. 
 
No sales data are routinely collected in New Zealand although anecdotally, sales of 
one leading brand of nicotine-free e-cigarette have increased 20% year-on-year for 
the past five years. No adverse events attributable to ENDS have been recorded on 
the Centre for Adverse Reactions Monitoring (CARM) database.  
 
In New Zealand, nicotine is classified as a medicine and regulated as such under the 
Medicines Act. It is illegal to sell e-cigarettes (with or without nicotine) that claim to 
help smokers quit, and it is illegal to sell e-cigarettes that look like a tobacco product 
(or pipe) to minors. It is, however, legal to sell e-cigarettes without nicotine, so long 
as no therapeutic claims are made. It is also legal to import nicotine and nicotine-
containing cartridges for ENDS for personal use. 
 
The categorisation for regulatory purposes therefore depends on how a product is 
presented for sale, including the intended use claimed by the supplier and whether 
this use has a therapeutic purpose. 
 
The Ministry of Health’s advice to the public and healthcare providers is that “e-
cigarettes are not proven for use in cessation and should not be promoted as such. 
Only evidence-based medications should be offered.”  
 
In reality, ENDS are readily available in some pharmacies, convenience stores and 
shopping malls, and current regulations offer no protection for users. These products 
are still legal to use in indoor areas at the facility owner’s discretion. Anecdotally, 
doctors are advising smokers to try e-cigarettes if they’ve failed to quit using other 
means. ENDS are already established in the marketplace, and other ANDS will be 
arriving soon. 
 
Other relevant legislation includes the Smoke-free Environments Act (1990) and 
subsequent amendments that prohibits the sale of tobacco-related products 
(including toy cigarettes) to minors and prohibits oral tobaccos, although nasal snuff 
is legal.  
 
There has been limited debate so far about the place of tobacco harm reduction – in 
particular ENDS and ANDS – in New Zealand’s tobacco control strategy. Apart from 
the broad goal of a smoke-free nation, there is no clear consensus on what the wider 
tobacco control goal should be: is it ending all tobacco use, getting rid of nicotine or 
reducing harm from smoked tobacco?  
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Meanwhile the public is confused, healthcare professionals are uncertain, the 
tobacco control sector is nervous, and nicotine-free e-cigarettes continue to be sold. 
 
One potential novel avenue for regulation is the new Psychoactive Substances 
Regulatory Authority (PSRA), established under the Psychoactive Substances Act 
2013. Through this authority, manufacturers of new psychoactive products (‘legal 
highs’, ‘party pills’, etc - defined as “a substance, mixture, preparation, article, 
device, or thing that is capable of inducing a psychoactive effect (by any means) in an 
individual who uses the psychoactive substance”) are required to apply for full 
product licences. They must submit data about the safety and quality of a product to 
demonstrate it poses no more than a low risk of harm to a consumer. The PSRA 
reviews the safety data, and may place further conditions on the product licence 
including a requirement for ongoing safety monitoring of products after they are on 
the market. An expert advisory group (IPSEAC) has been established to advise on risk 
assessment. 
 
IPSEAC’s advice is that psychoactive products should be treated in a similar way as 
pharmaceuticals intended for acute intermittent use. A risk score is generated on the 
magnitude of exposure and adverse events. The IPSEAC advice aligns with the risk 
management approach taken by both regulators and society towards alcohol: if the 
score for alcohol is ‘more than low risk of harm’, how would tobacco or nicotine 
score? 
  
“Anecdotally, doctors are advising smokers to try e-
cigarettes if they’ve failed to quit using other means. 
ENDS are already established in the marketplace, and 
other ANDS will be arriving soon…….. Meanwhile the 
public is confused, healthcare professionals are 
uncertain, the tobacco control sector is nervous, and 
nicotine-free e-cigarettes continue to be sold.” 
 
 
The Code of Manufacturing Process is intended to ensure that all psychoactive 
products on the market are made to a consistently high standard in clean, controlled 
environments. It provides quality control requirements for psychoactive substances 
and products, and outlines processes and information to be submitted to the PSRA 
for assessment.  
 
Under the new regimen, approved products cannot be sold from dairies, 
convenience stores, supermarkets, garages, temporary structures (e.g. marquees) or 
any place where alcohol is sold. They cannot be sold to minors, and retailers must 
have a licence to sell and cannot employ persons aged under 18 years to sell them. 
In addition, local authorities can restrict the location of retailers. 
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The application of this legislation is in limbo due to a knee-jerk response by 
government to public outcry over the issuing of interim licences to operate to ‘legal 
high’ vendors over the transition period. Interestingly, the legislation does not 
include any tobacco product, including nicotine, unless the product also contains a 
psychoactive substance as defined above.  
 
The Act would seem to be a very good regulatory ‘fit’ for all current and forthcoming 
ANDS. 
 
My current perspective is that ENDS could have a role to play in achieving New 
Zealand’s 2025 goal and beyond, but only as part of a comprehensive tobacco 
control package, in which tobacco prices were raised much higher and only ‘quality-
assured’ ANDS were available to smokers, with strict and enforced standards on 
marketing and sales to youth. 
 
Further discussion and informed debate towards consensus on a common end-point 
is required in the tobacco control community.  
 
We need more research into the roles of nicotine and behaviour in ANDS use, 
surveys of users, prospective studies to understand use patterns and health effects, 
use in specific populations, policy option simulations, modelling of trends in use and 
cessation, and learnings from the global ‘natural experiment’. 
 
The government should invest in ongoing monitoring and surveillance of products 
including adverse events, marketing, sales and use patterns, and provide better 
guidance for the public and health professionals. 
  
Finally, we could learn from and adapt New Zealand’s Psychoactive Substances 
regulatory regimen for ENDS and ANDS and, using a rational regulatory approach 
based on the continuum of harm, apply it to all tobacco products. 
 
  
Disclosures 
I was Principal Investigator of the ASCEND trial, a study funded in full by the Health Research Council 
of New Zealand. I have received benefit in-kind from a manufacturer of smoking cessation medications 
but I have not received any benefits from the manufacturers/retailers of ENDS/ANDS nor the tobacco 
industry. 
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RESEARCH AGENDA FOR ANDS & ENDS 
Professor Dorothy Hatsukami, University of Minnesota 
 
We have had much discussion about the promise and the perils of ENDS and other 
alternative nicotine delivery systems (ANDS) in the tobacco control and harm 
reduction landscape; but the important questions to address to determine the 
impact of ANDS and ENDS are if and what measures can be taken to minimise risk 
and maximise public health benefit? 
  
I recently co-chaired a National Institutes of Health-sponsored electronic cigarette 
workshop that identified five key categories of research gaps in this area,1 as 
outlined below with some of my own additions. 
 
Design and constituents 
In terms of design and constituents, key information required to inform any 
regulation strategy includes: 
• the characteristics of the different types and brands of ENDS 
(constituents, dose, stability under different storage conditions, 
voltage/temperature, particle size and density, lung deposition, 
change over use, etc.) 
• the impact of these characteristics on health, appeal (sensory aspects) 
and addiction potential of ENDS and how these features should 
evolve to minimise health risks. 
 
Indicators of health risk, addiction and sensory appeal 
Information required includes: 
• patterns of use and how use varies by product design 
• the health and nicotine addiction effects associated with dual use 
• the health effects from second- or third-hand exposure 
• the roles of nicotine and sensory aspects of ENDS use on its addiction 
potential  
• The extent to which ENDS should be addictive/attractive to promote 
complete switching but not increase uptake in youth. 
 
Behaviour of use, education and messaging 
We need to explore: 
• the impact of ENDS on current smokers, former smokers and never 
smokers in terms of uptake, cessation, dual use and relapse 
• the impact of ENDS on initiation and continued use of other tobacco 
products 
• how to communicate relative risk information to consumers, health 
professionals and adolescents without compromising public health 
• the type of warning labels that should be required  
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• how to minimise unintended consequences of concern (such as 
subverting public health tobacco control efforts to de-normalise 
smoking) 
• how access, cost and advertising messages affect uptake, dual use or 
continued use 
• how to promote transition to the safer product while discouraging 
non-tobacco users from staring and former tobacco users from 
relapsing (if ENDS are less harmful than tobacco). 
 
Cessation and harm reduction 
We want to know:  
• the efficacy of ENDS for the cessation of combustible tobacco or 
nicotine, either alone or combined with other therapies 
• the effectiveness of cigarette reduction (i.e. dual use) as a means for 
achieving cessation from cigarettes or from all tobacco or nicotine 
products 
• who should be targeted for cessation or cigarette reduction 
intervention with ENDS – e.g. should they be used first line or as a last 
hope 
• how cessation opportunities can be maximised. 
 
Methods and moderating factors 
Factors of importance include:  
• what standardised methods should be used to assess the effects of 
ENDS (e.g. clinical trial methods and outcomes, animal models) 
• what populations or factors moderate the effects of ENDS. 
 
The fact that these are constantly evolving products with no standardised product is 
a key challenge for ENDS research. There is no information available on the 
characteristics of various products, and generalising research from one country to 
another is problematic.  For these reasons, the recommendations for the National 
Institutes on Health were to: 
• develop one or more standardised ENDS (including both device and e-fluid) 
that will meet FDA application requirements 
• develop standardised methods to test ENDS for delivery characteristics, 
safety and unintended effects, and profile several of the most popular brands 
and types  
• consider a repository of products and possibly have sufficient quantities that 
can be provided to researchers 
• develop rapid research surveillance mechanisms and consider ad hoc sub-
studies using the Population Assessment of Tobacco and Health (PATH) 
cohort. 
 
 
1 Walton KM, Abrams DB, Bailey WC, et al. NIH Electronic Cigarette Workshop: Developing a 
Research Agenda. Nicotine and Tobacco Research 2014: doi: 10.1093/ntr/ntu214. 
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PART III: PANEL DISCUSSIONS 
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PANEL DISCUSSION 1 
 
Facilitator:  Dr Lyn Roberts 
 
Panel members: 
 
Professor Mike Daube: Director, Public Health Advocacy Institute and the McCusker 
Centre for Action on Alcohol and Youth 
 
Professor Simon Chapman: Professor of Public Health, University of Sydney 
 
Professor Ron Borland: Nigel Gray Distinguished Fellow in Cancer Prevention, Cancer 
Council Victoria 
 
Professor Wayne Hall: Director, Centre for Youth Substance Abuse Research, 
University of Queensland 
 
 
Discussion topics: 
 
A series of questions was posed to the panel by Dr Lyn Roberts following 
presentations delivered by the panel. Discussion topics are described below. 
 
Regulation of ENDS 
• the role of the TGA in regulating ENDS and whether the TGA has the powers 
required to properly regulate these products if an application was approved  
• the need for a regulatory framework that can both provide benefit to 
individuals but provide protection at a population level. 
 
The urgency to do more to reduce the harms from tobacco 
• whether current tobacco control initiatives are reducing harm at an 
acceptable pace 
• the risk of potentially negatively impacting prevalence trends from the re-
normalisation of smoking. 
• the fact that there will still be considerable levels of harm from tobacco 
experienced if smoking prevalence trends continue. 
 
The tobacco industry 
• the motivations behind the tobacco industry’s involvement in ENDS markets 
needs to be understood. 
  
 58 
PANEL DISCUSSION 2 
 
Facilitator: Dr Lyn Roberts 
 
Panel members:  
 
Ms Louise Galloway: Senior Advisor, Prevention and Population Health branch, 
Victorian Department of Health 
 
Dr Tony Gill: Senior Medical Advisor to the Market Authorisation Group, Therapeutic 
Goods Administration 
 
Ms Jacqui Bell: Legal Policy Advisor, Quit Victoria 
 
 
Discussion topics: 
 
Options for regulating ENDS in Australia 
• the suitability of the TGA as a regulatory body if no therapeutic claims are 
made (and nicotine-containing e-cigarettes are therefore an S7 poison) 
• the type of organisation that could apply for TGA approval of ENDS, the 
potential of another body initiating scheduling and the approval process 
• whether ENDS should be classified as a medicine or device (or both). 
 
Legal uncertainties and implications 
• the variation in ENDS characteristics (e.g. policing a ban on nicotine-
containing e-cigarettes in the presence of nicotine-free varieties)  
• uncertainties around legal issues for individuals (for whom it is currently 
illegal to possess ENDS), manufacturers (illegal to sell) and other companies 
(e.g. in maintaining a ban on ENDS in restaurants and on planes).  
 
Challenges for public policy 
• is it ethical to maintain access to a more harmful product and restrict less 
harmful ones? 
• in considering harms and benefits, we must have the evidence and open 
debate while understanding complex and changing policy contexts and 
economic and human rights impacts 
• the challenge for workplaces in considering policies on ENDS use, and the 
usefulness of a national/global position to give guidance and allow clarity and 
consistency 
• what advice should be offered to callers of the Quitline. 
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PANEL DISCUSSION 3 
 
Facilitator: Dr Lyn Roberts 
 
Panel members: 
 
Professor Mike Daube: Director, Public Health Advocacy Institute and the McCusker 
Centre for Action on Alcohol and Youth 
 
Professor Simon Chapman: Professor of Public Health, University of Sydney 
 
Dr Lorraine Baker: General Practitioner, Australian Medical Association (AMA) 
Victoria Board member 
 
Professor Ron Borland: Nigel Gray Distinguished Fellow in Cancer Prevention, Cancer 
Council Victoria 
 
Professor Wayne Hall: Director, Centre for Youth Substance Abuse Research, 
University of Queensland 
 
Professor Dorothy Hatsukami: Forster Family Chair in Cancer Prevention, Masonic 
Cancer Centre, University of Minnesota 
 
Dr Carmen Audera-Lopez: Acting Team Leader, Tobacco Free Initiative, WHO 
Regional Office for the Western Pacific 
 
 
Discussion topics:  
 
The research agenda 
• current research models are limited in their capacity to meet society’s needs. 
• current legislation limits our ability to research (e.g. we need an Australian 
cohort of users to understand behaviours and risks) 
• a multi-country large-scale cohort study may be the ideal, but difficult in 
practical terms 
• what research is needed before we take regulatory action, and what we can 
undertake afterwards? 
• what direct and indirect promotion of ENDS goes on, and what impact does 
this have on adults and children? 
• neither ENDS nor users represent homogeneous groups, and an 
anthropological approach is needed 
• the potential for ENDS to act as a gateway to cessation and a gateway to 
smoking is a vital issue that needs to be further explored.  
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Regulation options 
• it is important to clarify the role of ENDS – are they cessation aids, harm 
reduction products or both? 
• e-cigarettes do not appear to be significantly more effective than other 
cessation methods, but NRT is not particularly effective either, and 
registrations are likely to be approved because of this precedence 
• regulation needs to take research needs into account 
• something addictive being viewed as safe would be a major public health 
problem 
• we should move quickly to a coherent framework for regulation and then 
modify it as time and evidence moves on 
• innovative/evolving thinking is important (e.g. viewing nicotine in the same 
light as illicit drugs or psychoactive substances). 
 
Communication issues 
• terms need to be clarified – this may be a role for VicHealth 
• the importance of civilised discourse, particularly in light of an extremely 
challenging social media environment 
• there is currently misinformation at both extremes – i.e. that overestimates 
the efficacy of ENDS as a cessation aid and that overestimates the associated 
risks 
• what should the public message be, and who should provide it?  
o the NHMRC  
o the WHO (working on a statement, but it won’t be conclusive)?   
• what advice should doctors provide?  
o at present, ENDS represent an unlicensed product containing an 
unknown amount of an addictive substance and can’t be medically 
endorsed 
o should smokers also be told that used short-term as a cessation aid 
they’re probably safe? 
 
A broader harm reduction agenda 
• there is not enough discussion of other harm reduction strategies and focus 
on these, as well as complete cessation, should be maintained 
• there is the potential for ENDS to represent a passing fad (but issue of 
nicotine-addiction will remain) 
• can other harm reduction strategies learn from the proliferation of ENDS – 
e.g. their attractiveness over conventional NRT may increase their potency as 
short-term cessation aids. 
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PROGRAM AND SPEAKER PROFILES 
  
It’s killing me
Tobacco Harm Reduction Forum 
Reducing the harm from tobacco –  
an international perspective
Is there a place for a harm reduction approach  
as part of the Australian tobacco endgame?
Event program
Date:  Tuesday 15 July (9am–4pm) & Wednesday 16 July (9am–1pm) 2014 
Location:  ANZ Pavilion, Arts Centre, St Kilda Road, Melbourne
Time:  Registration from 8.30am
Facilitator: Dr Lyn Roberts
This event is fully catered.
TUESDAY 15 JULY
Agenda item Presenter Time
1. Registration from 8.30am
2. Facilitator welcome Dr Lyn Roberts 9.00am
3. Opening Professor David Hill 9.10am
4. VicHealth welcome Ms Jerril Rechter 9.20am
5. Is harm reduction necessary to eliminate smoking-related harm? Professor Ron Borland 9.30am
6. Harm reduction and ethical considerations for tobacco harm reduction Professor Wayne Hall 10.10am
Morning tea (10.40–11.10am)
7. Visualising possible scenarios using tobacco harm reduction approaches Professor Simon Chapman 11.10am
8.
Reducing harm from tobacco – priorities, past experience and the 
precautionary principle
Professor Mike Daube 11.50am
9. Panel discussion Dr Lyn Roberts 12.30pm
Lunch (1.15–2pm)
10. Review of current evidence for ANDS Associate Professor Chris Bullen 2.00pm
11.
Considering an economic evaluation of ANDS as part of a harm 
reduction approach in Australia
Dr Coral Gartner 2.30pm
12. Presentation from WHO Dr Carmen Audera-Lopez 3.15pm
13. Closing comments Dr Lyn Roberts 3.30pm
Afternoon tea / networking / conclusion
WEDNESDAY 16 JULY 
Agenda item Presenter Time
1. Coffee and tea from 8.30am
2. Welcome Mr Peter Gordon 9.00am
3. Experience of e-cigarettes in the UK Mr Alex Gyani 9.30am
4. US position on harm reduction and ANDS Professor Dorothy Hatsukami 9.45am
5. New Zealand – summary of current research, position and debate on 
tobacco harm reduction
Associate Professor Chris Bullen 10.15am
6. Panel discussion Ms Louise Galloway
Dr Tony Gill
Ms Jacqui Bell
10.45am
Morning tea (11.20–11.40am)
7. Challenges for future research for ANDS Professor Dorothy Hatsukami 11.40am
8. Panel discussion Professor Mike Daube
Professor Simon Chapman
Dr Lorraine Baker
Professor Ron Borland
Professor Wayne Hall
Professor Dorothy Hatsukami
Dr Carmen Audera-Lopez
12.10pm
9. Final summary Dr Lyn Roberts 12.50pm
Lunch and conclusion of forum
It’s killing me
It’s killing me
Tobacco Harm Reduction Forum 
Reducing the harm from tobacco –  
an international perspective
Featuring leading Australian and international experts
15 & 16 July 2014, Melbourne
Dr Carmen Audera-Lopez
Dr Audera-Lopez is the Acting Team  
Leader of the Tobacco Free Initiative,  
WHO Regional Office for the Western 
Pacific. She started her career as a 
laboratory researcher in allergy and 
immunology and for 10 years worked mainly 
in the development of innovative vaccines 
for allergy immunotherapy in the USA and 
Spain. Since obtaining a master’s degree in 
International Public Health she has been 
working for the past 18 years in different 
areas of public health, including HIV/AIDS, 
tobacco control and patient safety.
Dr Lorraine Baker 
Dr Baker is a general practitioner and 
graduate of The University of Melbourne 
(1979). After 2 years at the Queen Victoria 
Medical Centre she obtained a Diploma of 
Obstetrics and moved into rural general 
practice. In 1983 she founded the Belmore 
Road Medical Centre, which she has owned 
and operated with her husband since he 
joined her in 1984. She was one of the 
first students to enrol in the Graduate 
Diploma in Women’s Health – a course that 
stimulated a lasting interest in the social 
determinants of health.
Dr Baker was founding Chair of the Inner 
East Melbourne Division of General 
Practice. After serving on the AMA Victoria 
Council she was elected to the Board 
in 2010 and re-elected in May 2013. 
Involvement with the AMA allows her to 
work in various ways for the profession 
and for public health. In 2011–12 she 
served on the State Government Whole-
of-Government Alcohol and Other Drugs 
Advisory Group. Currently she serves on 
the Department of Health Working Group 
‘Supporting patients to be smoke-free’, a 
pilot project in Victorian public hospitals. 
Ms Jacqui Bell 
Ms Bell is Quit Victoria’s Legal Policy 
Adviser, responsible for providing technical 
advice to Quit’s policy and leadership 
team on tobacco control legal policy 
issues arising at the local, state, national 
and international levels. Ms Bell has 
undertaken extensive work reviewing laws, 
regulations and policy issues relevant to 
e-cigarettes in Australia and overseas, 
which informed the Cancer Council 
Australia and National Heart Foundation 
position statement on e-cigarettes.  
Ms Bell has previously worked in private 
practice as an employment lawyer and in 
law reform advocacy roles for the peak 
bodies of community legal centres in 
Victoria and the community managed 
mental health sector in Western Australia. 
Professor Ron Borland 
Prof. Borland is the Nigel Gray 
Distinguished Fellow in Cancer Prevention 
at The Cancer Council Victoria (Australia) 
where he has worked for over 25 years.  
He also has an honorary professorial 
position at The University of Melbourne.  
He has over 300 peer-reviewed 
publications, mostly related to aspects  
of tobacco control. He is one of the 
Principal Investigators of the International 
Tobacco Control Policy Evaluation Project 
– an international collaboration currently 
active in more than 20 countries. 
Prof. Borland’s work is designed to 
understand the impact on smokers of 
tobacco control policies, to help design 
better systems for regulating tobacco, 
to better understand the challenges of 
preventing relapse, and to develop and 
evaluate mass-disseminable strategies 
for helping smokers quit. He has just 
published a book on a comprehensive 
theory of Hard to Maintain Behaviour 
Change based largely on the challenges  
of smoking cessation.  
Associate Professor Chris Bullen 
Assoc. Prof. Bullen is a medical graduate 
of the University of Auckland and an 
academic public health physician. His 
interests in public health and research 
developed while he was working in 
Papua New Guinea for almost 8 years. 
He trained in Public Health Medicine 
and joined the University of Auckland’s 
Clinical Trials Research Unit in 2003 as 
a Senior Research Fellow, and in 2009 
was appointed Director of CTRU, where 
he oversaw its transformation into the 
National Institute for Health Innovation, 
one of New Zealand’s leading health 
research groups.  
In addition to this role, Assoc. Prof. Bullen 
teaches public health to undergraduate 
medical students and until recently was 
Deputy Head of the School of Population 
Health. 
His recent research interests have focused 
on tobacco control, an area in which he 
has published widely. He was principal 
investigator of the ASCEND trial, the 
largest randomised trial of e-cigarettes 
for smoking cessation yet conducted, 
and is co-director of the New Zealand 
Tobacco Control Research Turanga, a 
$5million 4-year program of strategic 
tobacco control research funded by the 
New Zealand Ministry of Health aimed 
at interventions to reduce smoking 
prevalence to achieve the goal of a 
‘Smokefree New Zealand by 2025’. 
He is a Fellow of the Faculty of Public 
Health Medicine, a Fellow of the New 
Zealand College of Public Health Medicine, 
a member of the Society for Research 
on Nicotine and Tobacco, and a Board 
member of the New Zealand Heart 
Foundation.
Professor Simon Chapman AO PhD 
FASSA Hon FFPH (UK)
Prof. Chapman is a Professor in Public 
Health at the University of Sydney. He has 
published 480 articles in peer-reviewed 
journals and 17 books and major reports. 
His h-index is 48 and his work has been 
cited over 8550 times. His Public Health 
Advocacy and Tobacco Control: Making 
Smoking History was published by 
Blackwell (Oxford) in 2007. His co-authored 
Let Sleeping Dogs Lie: What men should 
know before being tested for prostate cancer 
was published by Sydney University Press 
in 2010.  
In 1997 Prof. Chapman won the WHO’s 
World No Tobacco Day medal. In 2003 he 
received the American Cancer Society’s 
Luther Terry Award for outstanding 
individual leadership in tobacco control.  
In 2008 he won the NSW Premier’s Cancer 
Researcher of the Year medal, the Public 
Health Association of Australia’s Sidney 
Sax medal, and was a NSW finalist in 
Australian of the Year. He was deputy 
editor (1992–97) then editor (1998–2008) 
of the British Medical Journal’s Tobacco 
Control  and is now its editor emeritus. In 
2013 he was made an Officer in the Order 
of Australia for his contributions to public 
health and named 2013 Australian Skeptic 
of the Year.
Prof. Chapman’s current research involves: 
examining how health issues are covered 
in news media; characteristics of public 
health research (and its dissemination) 
which impact on public health policy; and 
the natural history of unassisted smoking 
cessation. 
Professor Mike Daube AO
Prof. Daube is Professor of Health Policy 
at Curtin University, where he is Director 
of the Public Health Advocacy Institute and 
the McCusker Centre for Action on Alcohol 
and Youth. Before this he was Director 
General of Health for Western Australia 
and Chair of the National Public Health 
Partnership. 
Prof. Daube is President of the Australian 
Council on Smoking and Health, Co-Chair 
of the National Alliance for Action on 
Alcohol, Patron of Local Drug Action Groups 
Inc., and chair or member of many other 
boards and committees. He was previously 
President of the Public Health Association 
of Australia, Deputy Chair of the National 
Preventative Health Taskforce, and Chair 
of the Tobacco Expert Committee that 
recommended plain packaging and  
other measures. 
Prof. Daube has been active in health 
policy, tobacco control, alcohol and other 
areas in public health nationally and 
internationally for more than 40 years. 
He has published widely and received 
numerous awards from organisations 
including the WHO, the Australian 
Medical Association, the National Heart 
Foundation, the American Cancer Society’s 
Luther Terry Distinguished Career Award 
and many others. He is an Officer in the 
Order of Australia (AO).
Ms Louise Galloway
Ms Galloway is Senior Adviser for the 
Prevention and Population Health (PPH) 
branch in the Victorian Department 
of Health. PPH’s work focuses on the 
development and implementation of 
primary and secondary prevention policy 
and program initiatives for Victoria 
undertaken in conjunction with partner 
agencies including: government,  
funded agencies, primary health,  
other organisations and the community. 
Ms Galloway’s areas of responsibility 
include tobacco control, sexual health 
and viral hepatitis, cancer prevention 
and population screening, oral health 
promotion and women’s health. 
Ms Galloway has more than 10 years’ 
experience in population screening, 
including overseeing new technology 
initiatives in cancer screening and 
prevention. She is the Victorian 
representative on a number of state  
and national committees. 
Ms Galloway has a long history in the 
health system, having first practiced as 
a radiographer then undertaking policy 
roles in both the non-government and 
government sectors. She has a Master 
of Business Administration from The 
University of Melbourne.
Dr Coral Gartner
Dr Gartner is a research fellow (NHMRC 
Career Development Fellowship) with 
a background in environmental health 
and epidemiology. Her previous research 
has included control of the dengue fever 
vector, Aedes aegypti and risk factors for 
Parkinson’s disease. 
Dr Gartner’s current primary research  
field is in the area of tobacco control policy. 
Her research interests include tobacco 
harm reduction and monitoring community 
illicit drug use via wastewater analysis. 
Her research methods include  
secondary analysis of national survey  
data, epidemiological modelling and 
clinical trials.
Dr Tony Gill
Dr Gill is a public health physician who 
is currently the Senior Medical Adviser 
to the Market Authorisation Group at the 
Therapeutic Goods Administration (TGA). 
Since joining the TGA in 2010 his roles 
have included Director of the Experimental 
Products Section, Acting Principal Medical 
Adviser, and Senior Medical Adviser to 
the Office of Scientific Evaluation. In the 
TGA he has been involved in the regulation 
of unapproved therapeutic goods 
including the Special Access Scheme, 
the Authorised Prescriber Scheme, and 
clinical trials. He has also been involved 
in the clinical evaluation of biologicals and 
medical devices, as well as the scheduling 
of medicines.
Dr Gill graduated from the University 
of Adelaide in 1983. Prior to joining the 
TGA, Dr Gill spent his medical career as 
a medical officer in the Australian Army, 
rising to the rank of Brigadier. Dr Gill is 
on the Faculty Council of the Australasian 
Faculty of Public Health Medicine.
Peter Gordon
Mr Gordon is a lawyer in private practice 
and a leader in smoking and health 
litigation in Australia. He was first appointed 
to the VicHealth Board in 2006. During his 
time on the Board he has taken on the roles 
of Deputy Chair, Chair of Victoria Walks, 
and Chair of the Australian Community 
Centre for Diabetes. Mr Gordon is President 
of Footscray (Western Bulldogs) Football 
Club, and a former AFL Director (1990–93). 
He was founding co-chair of the McCabe 
Centre for Law and Cancer. He currently 
serves as Director of Gordon Legal, and 
Comprehensive Legal Funding LLC.
Mr Alex Gyani
Mr Gyani is a Senior Advisor with the 
Behavioural Insights team, a world-
leading social purpose company that helps 
organisations in the UK and overseas 
to apply behavioural insights in support 
of social purpose goals. His work with 
the team has predominately focused on 
getting people back into work, but he has 
also worked on developing mental health 
services, public health and wellbeing. 
He joined the team in March 2012 as 
a Research Fellow. He holds degrees 
in Psychology from the University of 
Oxford and the University of Reading. 
He is currently on secondment to the 
Department of Premier and Cabinet,  
NSW, for 18 months.
Professor Wayne Hall
Prof. Hall is a Professor and Director of 
the Centre for Youth Substance Abuse 
Research at the University of Queensland 
and a Professor of Addiction Policy at the 
National Addiction Centre, Kings College 
London. He also has visiting professorial 
appointments at the London School of 
Hygiene and Tropical Medicine and at 
the National Drug and Alcohol Research 
Centre, UNSW.  
Prof. Hall was formerly: an NHMRC 
Australia Fellow in addiction neuroethics 
at the University of Queensland Centre for 
Clinical Research and the University of 
Queensland Brain Institute (2009–2014); 
Professor of Public Health Policy in the 
School of Population Health (2005–09); 
Director of the Office of Public Policy 
and Ethics at the Institute for Molecular 
Bioscience (2001–05) at the University of 
Queensland; and Director of the National 
Drug and Alcohol Research Centre at 
UNSW (1994–2001).  
Prof. Hall has advised the WHO on: 
the health effects of cannabis use; 
the effectiveness of drug substitution 
treatment; the scientific quality of the 
Swiss heroin trials; the contribution of 
illicit drug use to the global burden of 
disease; and the ethical implications of 
genetic and neuroscience research on 
addiction.  
Professor Dorothy Hatsukami
Prof. Hatsukami is the Forster Family Chair 
in Cancer Prevention at the Masonic Cancer 
Center of the University of Minnesota 
and Professor of Psychiatry. She is the 
Associate Director of Cancer Prevention and 
Control and also Director of the Tobacco 
Research Programs. She also holds adjunct 
appointments in the Departments of 
Psychology and Division of Epidemiology  
in the School of Public Health.
Prof. Hatsukami has authored or co-
authored about 300 journal articles, 
monographs, book chapters, and other 
publications. She has expertise in the 
areas of nicotine addiction and treatment 
of nicotine addiction in smokers. She 
has also conducted extensive research 
in the area of smokeless tobacco. Most 
of her efforts in this area have been 
focused on development or testing of 
medications, including a nicotine vaccine 
and combination medications. Additionally, 
she has expertise in tobacco product 
evaluation and methods to reduce tobacco 
harm. She was the Principal Investigator of 
a Transdisciplinary Tobacco Use Research 
Center. Research ranged from constituent 
analysis of tobacco products, developing 
biomarkers of toxicant exposure and 
toxicity, examining animal and human 
models to test new tobacco products, and 
testing different approaches to tobacco 
harm reduction. 
Prof. Hatsukami has served on numerous 
national committees, is a past president 
of the Society on Research on Nicotine 
and Tobacco, and a past president of the 
College on Problems of Drug Dependence.  
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Professor David Hill AO
Prof. Hill is a behavioural scientist who 
completed his PhD in psychology at The 
University of Melbourne in 1984 while 
already holding a senior role at the  
(then) Anti-Cancer Council of Victoria.  
In response to the evident need to base its 
prevention programs on sound behavioural 
principles, the Council appointed Prof. 
Hill as the founding Director of the Centre 
for Behavioural Research in Cancer from 
1986. Later, in 2002, he became CEO of the 
Cancer Council Victoria. He retired from 
that position in 2011, but has remained as 
an Honorary Senior Associate. Prof. Hill is 
also an Honorary Professorial Fellow at The 
University of Melbourne and an Honorary 
Adjunct Professor at Monash University.  
He has been awarded an honorary MD 
by the University of Newcastle. His 
international work has included a 2-year 
term as President of the Union for 
International Cancer Control (UICC).
In his long career at the Cancer Council, 
Prof. Hill has been involved in research 
that underpins tobacco control programs 
and advocacy. The majority of his 200+ 
publications are on tobacco. With Dr Nigel 
Gray, he was the first to publish Australian 
population data (in the Medical Journal 
of Australia) on both adult and school-
age smoking prevalence. His perspective 
on tobacco control ranges from the 
momentous first Report of the College 
of Physicians of London on Smoking and 
Health in 1962 to the present day.
Dr Lyn Roberts AM
Dr Roberts was CEO of the National Heart 
Foundation of Australia from 2001 to 
2013. Dr Roberts has developed national 
cardiovascular health programs within 
Australia and is regarded as an expert 
on tobacco control matters as well as 
overweight and obesity programs. She 
has been a member of a number of expert 
advisory committees for the government 
and non-government sectors including the 
National Preventative Health Taskforce and 
is currently on the Board of Directors of the 
Australian Institute of Health and Welfare 
and was a member of the Australian 
National Preventive Health Agency Advisory 
Council. She was Chair of the Australian 
Chronic Disease Prevention Alliance from 
1999 to August 2008. Dr Roberts was 
elected to the Board of the World Heart 
Federation (WHF) in 2006, served as Vice 
President from 2009–10, and was a Board 
member until the end of 2012. 
In 1997, Dr Roberts was awarded an 
Order of Australia (AM) for service to the 
community and to health, particularly 
in the fields of health promotion, cancer 
prevention awareness and lifestyle 
education. In 2012, Dr Roberts was 
appointed as an Adjunct Professor,  
School of Exercise and Nutrition Sciences, 
Faculty of Health, Deakin University.
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Forum participants 
 
First Name Surname Company 
Felix Acker VicHealth 
Neil Angus VicHealth 
Luke Atkin Quit Victoria 
Carmen Audera Lopez World Health Organization 
Rachael Bagnall Cancer Council Queensland 
Emily Bain Cancer Council Victoria 
Lorraine Baker Australian Medical Association 
Mark Bandick Drug and Alcohol Services SA 
Catriona Bastian SANE Australia 
Megan Bayly Cancer Council Victoria 
Jacqui Bell Quit Victoria 
Catherine Bennett Deakin University 
Kate Bolaffi Heart Foundation (Victoria) 
Bruce Bolam VicHealth 
Ron Borland Cancer Council Victoria 
Robyn Bradley Victorian Aboriginal Community Controlled Health Organisation 
Emily Brennan Cancer Council Victoria 
Sophie Broughton-
Cunningham 
Quit Victoria 
Chris Bullen National Institute for Health Innovation 
Helen Catchatoor Australian Government Department of Health 
Simon Chapman Sydney University 
Richard Charles ReGen 
Nicola Clark ACT Health 
Jo Clarkson Healthway 
Cassandra Clayforth Cancer Council WA 
Eleanor Clune Independent contractor 
Emma Cook VicHealth 
Kirstan Corben Alfred Health 
Trish Cotter Victorian Comprehensive Cancer Centre 
Simon Crouch Heart Foundation 
Chris Cunningham Quitline (New Zealand) 
Attila Danko  
Mike Daube Curtin University 
Emma Dean Alfred Health 
Ben Dunstan Department of Health (Victoria) 
Matthew Duong NSW Department of Premier and Cabinet 
Sarah Durkin Cancer Council Victoria 
Stuart Ferguson University of Tasmania 
Carolyn Ford Quit Victoria 
Greg Ford Heart Foundation 
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Carrie Fowlie Alcohol Tobacco and Other Drug Association ACT (ATODA) 
John Fulcher VicHealth 
Louise Galloway Department of Health (Victoria) 
Jane Gardner VicHealth 
Coral Gartner University of Queensland 
Rudi Gasser Barwon Health 
Anthony Gill Therapeutic Goods Administration, Australian Government 
Department of Health 
Ruby Green VicHealth 
Rohan Greenland Heart Foundation 
Nathan Grills The Nossal Institute for Global Health, The University of 
Melbourne 
Alex Gyani Behavioural Insights Team 
Wayne Hall University of Queensland 
Margaret Hamilton VicHealth Board; Cancer Council Victoria (President) 
Caroline Hardiman VicHealth 
Todd Harper Cancer Council Victoria 
Dorothy Hatsukami University of Minnesota 
Linda Hayes Cancer Council Victoria 
David Hayne Lung Foundation Australia 
Kate Hayne Lung Foundation Australia 
David Hill Forum presenter 
Kylie Johnson Department of Health (Victoria) 
Kellie-Ann Jolly Heart Foundation (Victoria) 
Bill King Cancer Council Victoria 
Alvin Lee Quit Victoria 
Lin Li Cancer Council Victoria 
Kylie Lindorff Cancer Council Victoria 
Sian Lloyd Quit Victoria 
Clare Looker VicHealth 
Louise Lyons Victorian Aboriginal Community Controlled Health Organisation 
Sarah MacLean Onemda VicHealth Koori Health Unit, The University of 
Melbourne 
Raglan Maddox University of Canberra 
Sarah Maddox Quit Victoria, Cancer Council 
Sue Mc Gill VicHealth 
Candice McKeone VicHealth 
Rebecca Meldrum Neami National 
Adam Miller VicHealth 
Julie Anne Mitchell Heart Foundation NSW 
Mike Morgan The University of Melbourne 
Cassie Nicholls VicHealth 
Erica Nixon ACT Health 
Sean O’Rourke VicHealth 
Sindhu Parthasarathy The University of Melbourne 
Debbie  Prout  ERMHA/Monash Health 
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Paul Watkins ERMHA/Monash Health 
Kate Purcell Purcell Consulting 
Renee Railton Cancer Council Victoria 
Jerril Rechter VicHealth 
Patricia Ritchie Deakin University 
Maya Rivis VicHealth 
Lyn Roberts LR Associates 
Denise Rodeh Department of Health (Victoria) 
Robin Room Melbourne School of Population and Global Health, The 
University of Melbourne 
Heidi Rose Department of Health (Victoria) 
Emma Saleeba VicHealth 
Michelle Scollo Cancer Council Victoria 
Cathy Segan Cancer Council Victoria 
Robyn Selby Smith Norton Rose Fulbright 
Louisa Shepherd VicHealth 
Paula Snowden Quitline (New Zealand) 
Alana Sparrow Cancer Council SA 
Christian-
Paul 
Stenta VicHealth 
Scott Stirling National Stroke Foundation 
Maurice Swanson Heart Foundation WA 
Natalie Tan The Nossal Institute for Global Health, The University of 
Melbourne 
Lydia Thomsen Project Health 
Kimberley Tovey Cancer Council Victoria 
Melanie Wakefield Centre for Behavioural Research in Cancer, Cancer Council 
Victoria 
Scott Walsberger Cancer Council NSW 
   
Mark West Queensland Department of Health 
Rebecca Whitehead Queensland Department of Health 
Ben Williams Western Health Drug Health Services. 
Bryn Williams Quit Victoria 
Hua Yong Cancer Council Victoria 
David Young Cancer Council Victoria 
Stavroula Zandes Health & Wellbeing Training Consultants 
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Overview for VicHealth 
Melbourne, 23 June 2014 
Dr Nigel Gray  AO 
 
My global peregrinations have caught up with me. I am due in Lyon (France) to give a 
lecture on harm reduction and will be returning too late to attend the VicHealth 
meeting in Australia. This meeting is about harm reduction also. Observation of 
recent events, blogs and local newsletter coverage prompt me to put on paper a 
global overview for circulation to several different audiences in an effort to put more 
of us on the same page.  
 
I attach for those who didn’t hear it the keynote address I gave to the Boston 
Conference of SRNT (note: see next section). Some of you have the slides. 
 
In essence, my commitment at this time is to develop a consensus on the issue of 
harm reduction as it can be applied to the cigarette. To justify this I will start with 
the issue of e-cigarettes (I will refer to as ENDS). 
 
I was disappointed to discover at the recent meeting of SRNT in Seattle that the 
horse has bolted and that almost all of you are using the term ‘e-cigarettes’. This is a 
mistake. Using the term ‘cigarette’ to describe the current mixtures of clean nicotine 
with warmed up carriers brings the product automatically into the restrictions 
applied to tobacco cigarettes and will provoke a lot of measures aimed at tobacco 
cigarettes. This may happen formally or informally - many restaurant owners in 
Australia are forbidding use of ENDS by vapers to be consistent with current law, but 
also current prejudice, against cigarette smoking. 
 
Clive Bates’ blog, to which I occasionally contribute, is populated by a galaxy of 
people supporting ENDS and the view that they are likely to be effective harm- 
reduction products. Perhaps wrongly, I signed their letter to Margaret Chang seeking 
support from WHO for acceptance of this view – WHO is seen as antagonistic to this.  
 
The response has provoked an argument full of assertions and little real evidence so 
here is my current position. 
 
Harm reduction is never going to do miracles. If India swapped their horrible 
chewing mixtures for snus, it might seriously reduce mortality. This won’t happen in 
a short time. 
ENDS are never going to do any more than the current NRT products are doing – 
which is not much. NRT may have doubled the rate of cessation but there are still 
continuing smokers out there who will be left with the current risk of tobacco 
cigarettes. These are often the less advantaged in society.   
 
The Australians who led the plain packaging are rightly apprehensive of ENDS, as 
Australia forbids the sale of smokeless tobacco products. We grabbed the chance to 
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do so, opportunistically, when BAT was trying to push the low-tar virtues of their 
tobacco substitute with Skoal Bandits. 
 
One of the main reasons that Australia was able to bring in plain packaging – apart 
from their political expertise – was the highly effective campaign of ‘de-
normalisation’ (defined as trashing the tobacco industry’s reputation) in which I was 
certainly involved between 1968 and 1995. The threat of ENDS to these 
sophisticated public health workers is the possibility – greatly feared – that ENDS 
could be the thin edge of the wedge to allow re-normalisation, and especially the 
possibility of glossy television advertising of ENDS which might well undo the 
excellent work that went into the almost total eradication of advertising for tobacco. 
They think, as do I, that ENDS are not going to do any more than NRT and they are 
likely to restrict or ban them rather than take a risk.  
 
I see the same approach as the reason that I have not been able to persuade my 
Australian colleagues that the work done by TobReg on the establishment of upper 
limits for carcinogens and toxins in tobacco cigarettes should be fought for 
vigorously. This approach has been recognised in the reports of the Australian 
committee that did the work on plain packaging but the approach was not made into 
law and it will probably not become law for a while yet, as the political situation is 
very unstable in Australia and no one would take a risk by putting legislation to the 
current parliament. 
 
I remain of the view that content of cigarettes should be regulated and have said so 
in my keynote address at the SRNT meeting in Boston in 2012. I have also developed 
it as a paper for TobReg but due to time shortage it was not fully considered at the 
last meeting so it will be published as a paper in the next TobReg Technical Report.   
 
My hope is that the view put in this paper will be accepted by those who are 
concerned about the possibility that we could be heading for a re-run of the low tar 
campaign. The plea is to recognise just how big (in fact huge) the differences 
between the contents of brands are. 
Clearly there is a spectrum of harm within the territory labelled as “cigarette” and it 
is set out in a table prepared for my next lecture in Lyon. When I last saw him in 
Boston, Mitch Zeller was of the same opinion, but the FDA is still beset by squadrons 
of lawyers and I don’t expect that regulation of tobacco content and emissions will 
come next week.                         
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This table shows the results of a comparison between Philip Morris brands published 
by Counts et al. It is clear that the variation between all the brands is enormous and I 
find it impossible to believe that the brands of higher emissions are not seriously 
more dangerous than those of lower emissions. 
 
This cannot be proved or disproved by any ethical clinical trial. Similarly, it cannot be 
proved that the relative increase in adenocarcinoma in the US is directly related to 
specific elements of the cigarette but it is certainly clear that this rise is due to 
changes in the cigarette – which is now more dangerous than it was thirty years ago.  
There is no other explanation. The almost certain candidates within the smoke are 
filter-ventilation and TSNA. 
 
Those who are reluctant to accept this proposition are largely driven by the 
(understandable) fear that the industry will somehow manage a return to the 
advertising of the ‘safer’ cigarette we experienced during the low tar campaign. The 
answer is that there will be no such advertising because the higher emitting brands 
would be removed from the market under the principle of mandating upper limits 
proposed by TobReg in TRS number 951. However, the limits proposed here are 
much lower than those suggested by TobReg in TRS 951. A threefold maximum 
would be generous to the industry, but feasible. 
 
These issues are certainly in the mind of the US FDA. 
 
Below are the trends of adenocarcinoma in the US. 
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Sadly, Dr Nigel Gray AO passed away in December 2014. He will be long remembered for his 
huge contribution to the health of all Australians and beyond. 
 
Dr Gray was an eminent author, advocate and scientist who made a significant and lasting 
contribution to health promotion, most notably in the reduction of tobacco smoking.  
 
He was instrumental in the establishment of VicHealth, was on its first Board, and was a 
much valued Patron of VicHealth. His clear vision for a foundation and his determination 
were critical to VicHealth's early success, and helped change the landscape of tobacco 
control and health promotion in Victoria forever. 
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Paper – Dr Nigel Gray, AO: “Nicotine yesterday, today and tomorrow: a 
global review 


































